All relevant data are within the manuscript and its Supporting Information files. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD012051.

Introduction {#sec001}
============

The composition of feeds used in salmon aquaculture has undergone significant changes over the last decades. The rapid growth in the aquaculture industry, but stable production of the major protein resource, fishmeal (FM), has led to increasing use of alternatives. Alternative protein sources are required to contribute to a well-balanced diet and to support optimal fish growth performance, health and disease resistance. Currently, proteins derived from insects \[[@pone.0218360.ref001]\], terrestrial animal co-products \[[@pone.0218360.ref002], [@pone.0218360.ref003]\] and microbial ingredients \[[@pone.0218360.ref004]\] are considered to be valuable alternatives. In commercial diets, plant-derived proteins have already replaced two third of the proteins of marine origin \[[@pone.0218360.ref005]\].

Plant ingredients are the most attractive protein sources due to their low cost of production, high protein content and availability \[[@pone.0218360.ref006]\]. Inclusion of plant ingredients in salmonid feeds can, however, result in reduced growth performance and feed utilization, and health issues due to anti-nutritional factors (ANF) \[[@pone.0218360.ref006], [@pone.0218360.ref007]\]. ANFs in plant-based diets have been associated with detrimental effects on the intestine of several salmonid species \[[@pone.0218360.ref007]\], and soybean meal-induced enteritis (SBMIE) is a well described condition in Atlantic salmon (*Salmo salar* L.) \[[@pone.0218360.ref008], [@pone.0218360.ref009]\]. Currently, in commercial salmon diets, the refined soy product with a reduced level of ANF, soy protein concentrate, is the primary protein source of plant origin \[[@pone.0218360.ref005]\] and has not been shown to cause pathological changes in the distal intestine (DI) of salmonids after short-term dietary exposure \[[@pone.0218360.ref009]\]. However, a certain degree of inflammation and ectopic epithelial cells have been observed in the DI of salmonids when fed diets based on FM and soy protein concentrate over a longer period of time \[[@pone.0218360.ref010]\].

Microbial ingredients have proven to be high-quality protein sources with the ability to mitigate the negative effects of plant-derived proteins \[[@pone.0218360.ref011]\]. Microbial ingredients such as yeast and bacteria contain bioactive compounds with immune-modulating properties that improve the changes caused by SBM \[[@pone.0218360.ref012]--[@pone.0218360.ref014]\]. Moreover, bacterial meal has been shown to prevent the development of SBMIE in a dose-dependent manner \[[@pone.0218360.ref015]\]. Mannan oligosaccharides, compounds found in yeast cell walls, have been used as a prebiotic and shown to protect the intestinal mucosa and reduce inflammation and leukocyte infiltration \[[@pone.0218360.ref016]\]. However, the degree of bioactivity of these compounds depends on the microbial origin as well as the fermentation conditions and downstream processing of the microbial product before incorporation into the salmon diet \[[@pone.0218360.ref011], [@pone.0218360.ref017]\].

Assessing the bioactivity of novel dietary microbial ingredients has traditionally involved the evaluation of local intestinal tissue responses, such as changes in morphology, gene expression or microbiome. Local intestinal responses can induce systemic responses that could contain new biomarkers for health and disease \[[@pone.0218360.ref018]\]. The innate immune system may respond to local inflammatory or immunomodulatory stimuli in the intestine of fish and in turn elicit changes systemically. The release of cytokines into the circulation stimulates hepatocytes to produce proteins and release them into the circulation to regain homeostasis \[[@pone.0218360.ref019]\]. Plasma proteomic analysis is a post-genomic tool that allows the investigation of complex biological systems involved in physiology and pathology. Plasma proteome profiles in response to certain inflammatory or immunomodulatory stimuli can be useful diagnostic tools for fish diseases and indicators of fish health.

In this study, an inactive dry yeast strain of *Candida utilis* (*C*. *utilis*) was used as an alternative protein source with functional properties in FM and SBM based diets. SBM was used as a dietary challenge to induce SBMIE. Increasing levels of *C*. *utilis* were included in the diets to evaluate the immunomodulating properties of the yeast, in particular, the ability to prevent and counteract SBMIE. We combine histomorphological evaluation, immunohistochemistry, morphometry and gene expression of the DI with plasma proteome analysis. By combining these methods, we aim to identify local intestinal tissue responses and changes in plasma protein profiles in Atlantic salmon resulting from dietary treatments. Our results show that inclusion of *C*. *utilis* as an alternative protein source does not alter the local morphology and immune cell population in the DI or induce major changes in the plasma proteins of Atlantic salmon.

Materials and methods {#sec002}
=====================

Experimental ingredient and diet preparation {#sec003}
--------------------------------------------

The inactive dry *C*. *utilis* yeast corresponded to a commercial product called Lakes States^®^ Type B produced by LALLEMAND SAS (Blagnac, France). [S1 Table](#pone.0218360.s001){ref-type="supplementary-material"} shows the proximate composition of the test inactive dry yeast. The crude protein content was determined by multiplying nitrogen content by a conversion factor of 6.25. All diets used in this study were formulated to meet or exceeded the nutrient requirements of Atlantic salmon \[[@pone.0218360.ref020]\] ([Table 1](#pone.0218360.t001){ref-type="table"}), produced by extrusion technology at the Center for Feed Technology (FôrTek) at the Norwegian University of Life Sciences (Aas, Norway), and stored at -20°C prior to feeding. The extruded pellets were dried to \~ 6% moisture content before vacuum coating with fish oil. The diets consisted of a FM-based control diet (FM group) and the following six experimental diets; a diet containing 200 g/kg *C*. *utilis* (FM200CU group), and five diets containing 200 g/kg SBM together with 0 (SBM group), 25, 50, 100 or 200 g/kg *C*. *utilis* (SBM25CU, SBM50CU, SBM100CU and SBM200CU groups, respectively).

10.1371/journal.pone.0218360.t001

###### Ingredient and proximate chemical composition (g/kg) of control (FM) and experimental diets.

FM = Fishmeal; SBM = soybean meal; SBM25CU = soybean meal + 25 g/kg *C*. *utilis*; SBM50CU = soybean meal + 50 g/kg *C*. *utilis*; SBM100CU = soybean meal + 100 g/kg *C*. *utilis*; SBM200CU = soybean meal + 200 g/kg *C*. *utilis*; FM200CU = fishmeal + 200 g/kg *C*. *utilis*.

![](pone.0218360.t001){#pone.0218360.t001g}

  Ingredient *(g/kg)*                                                Experimental diets                                           
  ------------------------------------------------------------------ -------------------- ------- ------- ------- ------- ------- -------
  Fishmeal[^a^](#t001fn001){ref-type="table-fn"}                     425.4                193     193     190     190     190     269
  Soybean meal[^b^](#t001fn002){ref-type="table-fn"}                                      200     200     200     200     200     
  *Candida utilis*[^c^](#t001fn003){ref-type="table-fn"}                                          25      50      100     200     200
  Wheat gluten                                                       150.6                150     139.4   115.2   93.5    72.9    118.8
  Corn gluten meal                                                                        60      60      60      60              36.8
  Wheat flower                                                       168.6                181     167.4   169.6   142.9   132.3   166
  Fish oil[^d^](#t001fn004){ref-type="table-fn"}                     240                  186     186     186     186     179.2   186
  Choline chloride[^e^](#t001fn005){ref-type="table-fn"}             1.5                  1.5     1.5     1.5     1.5     1.5     1.5
  MCP[^f^](#t001fn006){ref-type="table-fn"}                          6.2                  10.8    10.8    10.9    10.9    10.8    9.6
  L-Threonine[^g^](#t001fn007){ref-type="table-fn"}                  0.9                  2.4     2.2     2.2     1.7     1.2     1.0
  Premix Fish[^h^](#t001fn008){ref-type="table-fn"}                  6.3                  6.3     6.3     6.3     6.3     6.3     6.3
  Rhodimet NP99[^i^](#t001fn009){ref-type="table-fn"}                                     2       2       2.2     2.2     2.6     1.5
  L-Lysine monohydrochloride[^j^](#t001fn010){ref-type="table-fn"}   0.5                  7       6.4     6.1     5       3.2     3.5
  Proximate chemical composition (*g/kg*)                                                                                         
  Dry matter                                                         936                  942     936     943     956     937     932
  Crude protein                                                      445                  409.1   401.9   397.5   400.3   383     394.4
  Crude lipid                                                        24                   22.4    22.4    22.4    22.7    22.2    22.4
  Starch                                                             253.2                182.0   181.7   175.6   186.5   177.5   187.1
  Gross energy MJ/kg                                                 90.5                 63.4    64.7    67.2    69.3    72.3    73.1
  Total ash                                                          14.0                 8.9     9.3     9.2     8.8     9.0     10.2
  Phosphorus                                                         113.2                143.8   140.3   144.3   130.6   116.2   138.1

^a^ LT fishmeal, Norsildmel, Egersund, Norway.

^b^ Soybean meal, Non-GMO, Denofa AS, Fredrikstad, Norway.

^c^ Lake States^®^ Torula, Lallemand, USA.

^d^ NorSalmOil, Norsildmel, Egersund, Norway.

^e^ Choline chloride, 70% Vegetable, Indukern s.a., Spain.

^f^ Monocalcium phosphate (MCP), Bolifor^®^ MCP-F, Oslo, Norway Yara,

^g^ L-Threonine, CJ Biotech CO., Shenyang, China.

^h^ Premix fish, Norsk Mineralnæring AS, Hønefoss, Norway. Per kg feed; Retinol 3150.0 IU, Cholecalciferol 1890.0 IU, α-tocopherol SD 250 mg, Menadione 12.6 mg, Thiamin 18.9 mg, Riboflavin 31.5 mg, d-Ca-Pantothenate 37.8 mg, Niacin 94.5 mg, Biotin 0.315 mg, Cyanocobalamin 0.025 mg, Folic acid 6.3 mg, Pyridoxine 37.8 mg, Ascorbate monophosphate 157.5 g, Cu: CuSulfate 5H~2~O 6.3 mg, Zn: ZnSulfate 151.2 mg, Mn: Mn(II)Sulfate 18.9 mg, I: K-Iodide 3.78 mg, Ca 1.4 g.

^i^ Rhodimet NP99, Adisseo ASA, Antony, France.

^j^ L-Lysine CJ Biotech CO., Shenyang, China.

Fish husbandry and feeding trial {#sec004}
--------------------------------

The experiment was conducted according to laws and regulations for experiments on live animals in EU (Directive 2010/637EU) and Norway (FOR-2015-06-18-761). Vaccinated salmon (Aquavac PD7, MSD Animal Health, Bergen, Norway) were acquired from Sørsmolt AS (Sannidal, Norway) and maintained according to the guidelines established by the Norwegian Animal Research Authority at the Research Station Solbergstrand of Norwegian Institute of Water Research (Drøbak, Norway). Fish were acclimated to seawater, housed in 300 L tanks supplied with ultraviolet light treated seawater (8 °C; 34.5 g/L NaCl) in a 7--8 L per min flow-through system, and fed with a commercial marine-based compound feed not containing soybean-derived products (3-mm pellet; Polarfeed AS, Europharma, Leknes, Norway) under continuous light during a 4-month period prior to conducting the feeding trial. The water temperature, dissolved oxygen and pH level were measured and recorded daily. At the beginning of the experiment, 360 fish (average initial body weight of 526 g) were randomly assigned to 18 tanks (20 fish/tank) and acclimated to the FM based control diet for two weeks prior to feeding experimental diets. Feeding was approximately 20% in excess twice daily using automatic belt feeders based on a daily estimate of fish biomass and uneaten feed per tank, which was collected from the tank outlet after each feeding period. Following the acclimation period, each experimental diet was randomly allocated to the fish tanks (two tanks/diet) and fed for 30 days (period 1) as described above. After 30 days, the feeding strategy was changed, and new diets were fed for 7 days (period 2). As a control, one fish group received FM through the experiment. To assess whether *C*. *utilis* were able to counteract enteritis induced by SBM, four fish groups received SBM diets combined with different inclusions levels of CU (i.e. SBM25CU, SBM50CU, SBM100CU, SBM200CU) in period 1. One fish group received FM200CU in period 1 to evaluate if *C*. *utilis* in combination with FM alone would affect the DI. In period 2, the ability of *C*. *utilis* to prevent SBMIE was assessed as the diet was changed to SBM in this group. Finally, three fish groups were fed SBM diet to induce SBMIE in period 1, and in period 2 the diets were changed to either FM, FM200CU and SBM200CU to evaluate if these diets were able to reverse SBMIE. The feeding strategy is illustrated in [Fig 1](#pone.0218360.g001){ref-type="fig"}.

![Experimental design.\
The adaptation period of 14 days was followed by experimental period 1 that lasted for 30 days. In experimental period 2, there was a shift in diets and this period lasted for 7 days. Sampling points are day 0, 7, 30 and 37. FM = Fishmeal; SBM = soybean meal; SBM25CU = soybean meal + 25 g/kg *C*. *utilis*; SBM50CU = soybean meal + 50 g/kg *C*. *utilis*; SBM100CU = soybean meal + 100 g/kg *C*. *utilis*; SBM200CU = soybean meal + 200 g/kg *C*. *utilis*; FM200CU = fishmeal + 200 g/kg *C*. *utilis*.](pone.0218360.g001){#pone.0218360.g001}

Sample collection {#sec005}
-----------------

At each sampling point (0, 7, 30 and 37 days), 8 fish per diet (4 fish per tank) were randomly selected and anesthetized by immersion in 60 mg/l of tricaine methanesulfonate (MS-222, Sigma-Aldrich, MO, USA) and subsequently euthanized by a sharp blow to the head. Before dissecting fish, fish weights and lengths were recorded, and blood samples were taken from the *vena caudalis* (tail vein) using a heparinized syringe and centrifuged (1300--2000 x g for 10 min) to isolate blood plasma, which was aliquoted and stored at --80°C until proteomic analysis was performed. DI tissue was sampled and kept in RNAlater^®^ (Merck KGaA, Darmstadt, Germany) at 4°C for 24 h, and then at --80°C, until RNA extraction. DI tissue samples were also collected and preserved for subsequent histology, morphometry and immunohistochemistry.

Histology, immunohistochemistry and morphometric measurements {#sec006}
-------------------------------------------------------------

### Histology {#sec007}

Approximately 1 cm segment of the DI was open longitudinally and the intestinal content was carefully removed. The tissue was fixed in 10% formalin for 48 h at room temperature and further processed according to routine histological procedures. Briefly, tissue was embedded in paraffin with an orientation to ensure longitudinal sectioning. Sections (2 μm) of paraffin-embedded DI tissue were mounted on glass slides (Menzel Gläser, Thermo Fisher Scientific, Braunschweig, Germany) and processed for staining with hematoxylin and eosin. A blinded, semi-quantitative histological scoring of the DI was performed using the criteria described in detail by Baeverfjord and Krogdahl \[[@pone.0218360.ref008]\]. Briefly, the criteria were: 1) shortening of both the simple and complex intestinal mucosal folds, 2) appearance of the enterocytes including supranuclear vacuolization, cellular heights and presence of intraepithelial lymphocytes (IELs), 3) widening of the central lamina propria of the simple and complex folds by connective tissue and 4) infiltration of leucocytes in the lamina propria. Each criterion was given a score ranging from 0 to 2, and half scores were included (i.e. 0, 0.5, 1, 1.5, 2) \[[@pone.0218360.ref013]\]. Score 0 indicated normal morphology and score 2 represented marked changes. Score 0.5 was regarded as changes within the normal range.

### Immunohistochemistry {#sec008}

Histological sections of DI from the fish sampled at day 30 (8 fish/diet), prepared as described above, were subjected for immunohistochemical analysis, and the following diet groups were included: FM, FM200CU, SBM, SBM25CU and SBM200CU. CD3ε and CD8α positive T lymphocytes were identified in DI tissue sections by immunohistochemistry using a monoclonal anti-CD3ɛ antibody (dilution 1:600) \[[@pone.0218360.ref021]\] and a monoclonal anti-CD8α antibody (kindly supplied by Karsten Skjødt, dilution 1:50) \[[@pone.0218360.ref022]\], respectively. This analysis was performed as follows: formalin-fixed, paraffin-embedded DI sections (4 μm) were mounted on poly-L-lysine-coated glass slides (Superfrost Plus, Thermo Fisher Scientific, Braunschweig, Germany) and left to dry at 37°C. The slides were incubated at 58°C for 30 min before deparaffinized in xylene and rehydrated in graded alcohols to distilled water. Antigen retrieval was done by using hydrated autoclaving at 121°C for 15 min in 0.01 M citrate buffer, pH6. Endogenous peroxidase was inhibited with 0.05% phenylhydrazine (0.05%; Sigma-Aldrich, MO, USA) in phosphate buffered saline, preheated to 37°C, for 40 min. The sections were stored in PBS overnight at 4°C and then incubated with normal goat serum (dilution 1:50; Sigma-Aldrich) in 5% bovine serum albumin /0.05 M tris-buffered saline to avoid non-specific binding for 20 min. The blocking solution was tapped off without washing, and the sections were incubated with primary antibody diluted in 1% bovine serum albumin/Tris-buffered saline for 1 h. Control sections were incubated with only 1% bovine serum albumin. The sections were incubated in the kit polymer-HRP anti-mouse (Dako En Vision+ System-HRP, Dako, Glostrup, Denmark), as a secondary antibody, for 30 min. Peroxidase activity was detected with 3,3'-diaminobenzidine following the kit procedure. The sections were counterstained with hematoxylin for 30 s followed by washing in distilled water before mounting with Aquatex (Novoglas Labortechnik Langenbrinck, Bern, Germany). Unless otherwise stated, the sections were washed three times with phosphate buffered saline for 5 min between each step. All incubations took place in a humid chamber at room temperature.

### Morphometric measurements and calculation of immune cell density {#sec009}

Morphometric measurements and calculation of the density of immune cells were performed from immunohistochemically labelled sections mentioned above. ImageJ software, version v1.51r \[[@pone.0218360.ref023]\], was used to perform the measurements and calculations. Images were captured with a Zeiss Axiocam 506 color camera connected to a light microscope (Zeiss Axio Imager M2, Carl Zeiss, Germany) at a 10 X magnification. The measurement scale was set to 2.26 pixels/μm in ImageJ and the measurements were converted from μm to mm. Counting of immunohistochemically labelled cells was performed using the multi-point tool. The freehand selection and segmented line selection were used to measure fold area and height, respectively. The fold height was measured from stratum compactum to the tip of the epithelium lining the fold ([S1 Fig](#pone.0218360.s004){ref-type="supplementary-material"}). The fold area was measured from stratum compactum, including the middle of the fold base on each side, and the whole simple fold ([S1 Fig](#pone.0218360.s004){ref-type="supplementary-material"}). The immunohistochemically labelled cells were counted within the measured area of the simple fold. The density of CD3ɛ- or CD8α-labelled cells was calculated as follows: Cell density = (no. of labelled cells)/area. Simple folds were subjected to all the measurements mentioned above and the folds were selected as the first appropriate simple fold located to the left of a complex fold. An appropriate fold was defined as a fold that appeared long, not bent and had an intact epithelium that was attached to the basement membrane all the way to the tip of the fold. Between 2--6 measurements were collected from each individual with a total of at least 30 measurements from each group for each measurement. A mean for each individual was calculated based on the measurements.

RNA isolation, cDNA synthesis, quantitative PCR {#sec010}
-----------------------------------------------

A small piece of DI tissue (approximately 0.5 cm) from FM, FM200CU, SBM and SBM200CU diet groups (8 fish/diet) at day 30 were subject to gene expression analysis. Total RNA was extracted and purified using RNeasy^®^ 96 kit (Qiagen, Valencia, USA) and QIAcube^®^ HT system (Qiagen), according to the manufacturer's protocol. After the first washing step, on-column DNase treatment was performed using PureLink TM DNase kit (Thermo Fisher Scientific, Waltham, Massachusetts). RNA concentration and quality were measured using NanoDrop TM 8000 spectrophotometer (Thermo Fisher Scientific). Purified total RNA was stored at −80°C until further analysis.

Prior to cDNA synthesis, all samples were normalized to 400 ng/μL. cDNA synthesis was performed using AffinityScript QPCR cDNA Synthesis kit following the manufacturer's guidelines (Agilent Technologies, Santa Clara, CA, USA). The total reaction volume was 10 μL using 5 μL of Mastermix, 1.5 μL random hexamer primers, 0.5 μL AffinityScript RT/ RNase Block enzyme mixture and 3 μL DNase treated RNA. The resulting cDNA was stored at −80°C before use.

All quantitative PCR (qPCR) reactions were performed in duplicates and conducted in 96 well plates on LightCycler^®^ 480 system (Roche Diagnostics, Mannheim, Germany). Each reaction consisted of a total amount of 12 μL divided into 6 μL LightCycler 480 SYBR Green I Master (Roche Diagnostics), 2 μL primers (5μM), and 4 μL cDNA. The qPCR conditions were 95°C for 5 min before a total of 45 cycles of 95°C for 5 seconds, 60°C for 15 seconds, and 72°C for 15 seconds. To confirm amplification specificity, each PCR product was subject to melting curve analysis (95°C 5 s; 65°C 60 s; 97°C continuously). Primers tested are listed in [S2 Table](#pone.0218360.s002){ref-type="supplementary-material"}. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and hypoxanthine phosphoribosyltransferase I (HPRTI) were chosen as reference for normalization since these genes did not show significant differential expression between the diets and have previously been described as suitable reference genes in the DI of salmon \[[@pone.0218360.ref024]\]. The crossing point (Cp) values were determined using the maximum second derivative method on the basis of the LightCycler^®^ 480 software release 1.5.1.62 (Roche Diagnostics). The geometric mean of the CP-values for GDPH and HPRTI was used as an index. The qPCR relative expression of mRNA was calculated using the ΔΔCt method \[[@pone.0218360.ref025]\].

In-solution digestion and protein sequence analysis by LC-MS/MS {#sec011}
---------------------------------------------------------------

Proteomic analysis was performed, according to methods described by Lagos *et al*. 2017 \[[@pone.0218360.ref026]\], using four biological replicates per treatment of plasma taken at the end of the first feeding period (30 days) (FM, SBM, SBM200CU and FM200CU). In brief, frozen plasma (−80°C) was thawed and diluted to 40 μg of total protein in PBS, and the pH was adjusted to 8 by adding ammonium bicarbonate (Sigma-Aldrich, Darmstadt, Germany). Subsequently, the proteins were digested with 10 μg trypsin (Promega, sequencing grade) overnight at 37°C. The digestion was stopped by adding 5 μL 50% formic acid and the generated peptides were purified using a ZipTip C18 (Millipore, Billerica, MA, USA) according to the manufacturer's instructions, and dried using a Speed Vac concentrator (Concentrator Plus, Eppendorf, Hamburg, Germany). The tryptic peptides were dissolved in 10 μL 0.1% formic acid/2% acetonitrile and 5 μL analyzed using an Ultimate 3000 RSLCnano-UHPLC system connected to a Q Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a nanoelectrospray ion source. For liquid chromatography separation, an Acclaim PepMap 100 column (C18, 2 μm beads, 100 Å, 75 μm inner diameter, 50 cm length) (Dionex, Sunnyvale CA, USA) was used. The mass spectrometer was operated in the data-dependent mode to automatically switch between MS and MS/MS acquisition. Survey full scan MS spectra (from m/z 400 to 2,000) were acquired with the resolution R = 70,000 at m/z 200, after accumulation to a target of 1e5. The maximum allowed ion accumulation times were 60 ms. The proteomic analysis was performed by the Proteomic core facility of the University of Oslo. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE \[[@pone.0218360.ref027]\] partner repository with the dataset identifier PXD012051.

Data analysis {#sec012}
-------------

### Histology, morphometric measurements, T-cell density and gene expression {#sec013}

Non-parametric data from the histological evaluation were analyzed by Kruskal-Wallis followed by post hoc Dunn's test with a comparison of mean rank. Shapiro-Wilk normality test was used to test the normal distribution of the data from morphometric analyses and T-cell density and further analyzed by one-way ANOVA followed by Tukey's multiple comparisons test. Morphometric analyses and T-cell density analyses were performed at the individual level using the mean of measurements of between 2--6 simple folds per fish. Results of qPCR (means ± standard deviations) were analyzed using One-way ANOVA with Dunnett\`s multiple comparison test (*a* \< 0.0001). These analyses were performed in GraphPad Prism, version 7.00 and 8.0.1 (GraphPad Software Inc., San Diego, CA, USA).

### Proteomic data analysis {#sec014}

The resulting proteomic data, MS raw files, were analyzed using MaxQuant and Perseus version 1.6.0.7 based on MS1 intensity quantification. Then identifications were filtered to achieve a protein false discovery rate (FDR) of 1%. Peptide identification was determined using fragment mass tolerance for the MS1 6 ppm and the fragment mass tolerance for the MS2 20 ppm. MS/MS spectra were searched against the salmon proteome available in September 2019 (<https://www.uniprot.org/proteomes/query=taxonomy:82390>), and reverse database searches were used in the estimation of FDR. The analysis was restricted to proteins reproducibly identified in at least two of the four replicates per diet, making the minimum number of peptides used to identify each protein an average value of 2. Row-wise normalization was applied to provide Gaussian-like distributions \[[@pone.0218360.ref028]\] for adjusting the differences among protein data. Protein raw data were transferred to log normalization; missing value imputation was used to replace the not identified proteins on the quantitative analysis and then performed on autoscaled data (mean-centered and divided by the standard deviation of each variable) \[[@pone.0218360.ref029]\]. A diagnostic plot was utilized to represent normalization procedures for normal distribution assessments \[[@pone.0218360.ref030]\]. Volcano plot analysis and data modeling were performed in R, using R package MetaboAnalystR \[[@pone.0218360.ref028]\]. UniprotKB database was used for the functional annotation of the proteins.

Results {#sec015}
=======

Growth and general health {#sec016}
-------------------------

All groups of fish accepted their allocated diets and no significant differences were found in feed intake nor growth rate among dietary treatment. The average initial weight was 526 g and the average final weight was 667 g on day 37, considering that the weight was measured as bulk, this indicates that in general fish gained weight during the experimental period. The general health of the fish in this experiment was good, but two fish died during the experimental period, one from SBM50CU group and one from SBM100CU group, for unknown reasons.

Histology {#sec017}
---------

All fish sampled at day 0 showed normal DI morphology. Briefly, simple folds were long and slender with a thin lamina propria, whereas the complex folds were tall with a narrow lamina propria and a partial central core of smooth muscle. Intestinal epithelial cells were tall with the nucleus located basally, large vacuoles located apically and many IELs. Goblet cells were scattered among the epithelial cells towards the apex, and there was a higher presence of goblet cells at the apex of the complex folds. The lamina propria adjacent to the stratum compactum was thin and numerous eosinophilic granule cells were present.

At day 7 ([Fig 2A](#pone.0218360.g002){ref-type="fig"}), FM and FM200CU groups showed normal DI morphology as described above. In general, all fish groups fed diets containing SBM, including SBM diets with *C*. *utilis* inclusion, displayed changes in the DI morphology consistent with SBMIE (described in detail below). Nevertheless, in SBM25CU and SBM50CU, there was variation within the groups ranging from individuals showing no changes to other individuals with moderate changes in DI morphology.

![Histological evaluation.\
Histological evaluation of the distal intestine of Atlantic salmon based on atrophy, lamina propria, epithelium and edema at 7 (A), 30 (B) and 37 (C) days. Changes are scored from 0 to 2 where 0 indicates no changes and 2 indicates severe changes. Data are expressed as mean and standard deviation, n = 8 for all groups. Significant difference from the control fish fed FM based diet is denoted by an asterisk (\*) (p\<0.05; Dunn´s test). FM = fishmeal; FM200CU = fishmeal combined with 200 g/kg *C*. *utilis* (CU); SBM = soybean meal; SBM25CU = soybean meal with 25 g/kg CU; SBM50CU = soybean meal with 50 g/kg CU; SBM100CU = soybean meal with 100 g/kg CU; SBM200CU = soybean meal with 200 g/kg CU.](pone.0218360.g002){#pone.0218360.g002}

At day 30 ([Fig 2B](#pone.0218360.g002){ref-type="fig"}), no morphological changes were seen in the DI of FM and FM200CU groups ([S2A and S2B Fig](#pone.0218360.s005){ref-type="supplementary-material"}). However, a moderate SBMIE was present in the DI of SBM ([S2F Fig](#pone.0218360.s005){ref-type="supplementary-material"}), SBM100CU and SBM200CU ([S2E Fig](#pone.0218360.s005){ref-type="supplementary-material"}) groups. Both simple and complex folds were shorter with a widening of the lamina propria within the folds and adjacent to the stratum compactum. A fusion of the simple folds was frequently observed. There was an increased presence of connective tissue in the lamina propria and the increased infiltration of leucocytes consisted mainly of eosinophilic granule cells and to a lesser extent of lymphocytes. The intestinal epithelial cells showed a reduction in height with nucleus displaced in a more apical position and small supranuclear vacuoles. In SBM25CU ([S2C and S2D Fig](#pone.0218360.s005){ref-type="supplementary-material"}) and SBM50CU groups, there was still a variation within the groups as seen on day 7.

At day 37 ([Fig 2C](#pone.0218360.g002){ref-type="fig"}), fish previously fed SBM, either alone or in combination with *C*. *utilis*, had normal DI morphology after being fed FM for 7 days. Similarly, most of the fish that had diets changed from SBM to FM200CU had DI morphology regarded as normal, but there were some fish in these groups that had mild enteritis. Changing diet from FM200CU to SBM induced in general a mild SBMIE, whereas a shift from SBM to SBM200CU maintained a moderate SBMIE. The FM control group was normal, as described above.

No tank effects were observed at any of the sampling points. In [Fig 2A and 2B](#pone.0218360.g002){ref-type="fig"}, only fish from the tanks that were subjected to immunohistochemical analysis at day 30 are presented, i.e., two SBM-groups are omitted from the figure. Fish with diet shift from SBM combined with *C*. *utilis* to FM at day 37 had normal DI morphology but are excluded from [Fig 2C](#pone.0218360.g002){ref-type="fig"} as this group did not differ from the SBM group.

Immunohistochemistry, morphometry, density of immune cells {#sec018}
----------------------------------------------------------

At day 30, CD3ɛ positive cells showed an abundant presence at the base of the epithelium and extending along the entire length of simple folds of FM and FM200CU ([Fig 3A and 3B](#pone.0218360.g003){ref-type="fig"}) groups. Only a few CD3ɛ positive cells were observed in the lamina propria adjacent to the stratum compactum, and were rarely present in the lamina propria of the simple folds. A weak diffuse labelling was observed in the smooth muscle, which was interpreted as background labelling. The negative controls were blank.

![Immunohistochemical staining for CD3ɛ and CD8α positive cells at day 30.\
Immunohistochemical labelling (brown) showed an abundant presence of CD3ɛ positive cells at the base of the epithelium along the entire length of simple folds in all diet groups (A: FM200CU; D: SBM). At higher magnification, CD3ɛ positive cells were rarely present in the lamina propria of the simple folds in any of the diets (B: FM200CU; C: SBM). However, there was a higher number of CD3ɛ positive cells in the lamina propria adjacent to the stratum compactum in groups fed diets with SBM (D: SBM). CD8α positive cells were mainly found between the epithelial cells of all individuals of all diet groups (E: FM200CU; F: SBM200CU; G: SBM). Image A and D captured at 10x magnification, Image B, C, E, F and G captured at 40x magnification.](pone.0218360.g003){#pone.0218360.g003}

The density of CD3ɛ positive cells in the simple folds of groups fed diets containing SBM was increased compared with the density in FM group. IEL's that showed labelling for CD3ɛ were located as individual cells at the base of the epithelium, but occasionally clusters of CD3ɛ-labelled IEL's were observed. CD3ɛ positive cells were more frequent in the lamina propria adjacent to the stratum compactum of fish fed SBM compared with fish fed FM ([Fig 3D](#pone.0218360.g003){ref-type="fig"}), but there were only a few CD3ɛ-positive cells present in the lamina propria of the simple folds ([Fig 3C](#pone.0218360.g003){ref-type="fig"}).

CD8α-labelled IEL's showed the same distribution as the CD3ɛ-labelled IEL's being located basally between the intestinal epithelial cells in all diets ([Fig 3E--3G](#pone.0218360.g003){ref-type="fig"}). In general, the presence of CD8α-labelled IEL's was lower than the presence of CD3ɛ-labelled IEL's.

Morphometric measurements of simple folds, both length and area, revealed no significant differences between FM and FM200CU groups. The simple folds in the DI of fish fed SBM, SBM25CU and SBM200CU were significantly shorter and had a considerably smaller area than the simple folds in fish fed FM200CU and FM. There were no statistically significant differences between the simple folds of fish fed diets containing SBM either alone or combined with *C*. *utilis* ([Fig 4A and 4B](#pone.0218360.g004){ref-type="fig"}).

![Morphometry of simple folds in distal intestine at day 30.\
Morphometric measurements of fold length (**A**) and fold area (**B**) of the simple folds of the distal intestine, and the density of CD3ε- and CD8α-positive T-cells in simple folds including the lamina propria adjacent to the stratum compactum (**C** and **D**). Data are expressed as mean for each individual ± standard deviation (SD), n = 7 for the SBM diet and n = 8 individuals per diet for the remaining groups. Groups with different letters on the upper x-axis are significantly different (p\<0.05; Dunn's test).](pone.0218360.g004){#pone.0218360.g004}

The density of CD3ε and CD8α-labelled cells in fish of FM and FM200CU groups was significantly lower compared with the density in fish from groups fed diets containing SBM. There was a statistically significant difference between the density of CD8α-labelled cells in fish of SBM group and the density CD8α-labelled cells in fish from the SBM25CU (p = 0.0465) ([Fig 4D](#pone.0218360.g004){ref-type="fig"}).

Gene expression {#sec019}
---------------

Among the tested genes, only mRNA expression of Aquaporin 8 (*aqp8*) was significantly down-regulated in the SBM and SBM200CU groups compared with the FM control group ([Fig 5E](#pone.0218360.g005){ref-type="fig"}). There was no significant difference between FM200CU and the FM control group. The transcription levels of superoxide dismutase 1 (*sod1*), glutathione S-transferase alpha 3 (*gsta3*), annexin A1 (*anxa*), and catalase (*cat*) were not different among dietary groups (p \> 0.05) ([Fig 5A--5D](#pone.0218360.g005){ref-type="fig"}).

![Gene expression.\
Quantitative PCR analyses of (**A**) superoxide dismutase 1 (*sod1*), (**B**) glutathione S-transferase alpha 3 (*gsta3*), (**C**) annexin (*anxa*), (**D**) catalase (*cat*) and (**E**) aquaporin 8 (*aqp8*) genes in the DI of Atlantic salmon fed a control fishmeal-based diet (FM), a diet containing 200 g/kg *Candida utilis* (FM200CU), and a diet containing 200 g/kg soybean meal (SBM) and one diet with 200 g/kg SBM in combination with 200 g/kg of *C*. *utilis* (SBM200CU) for 30 days. Data are mean --ΔΔCT ± SE (n = 7 for FM diet, n = 8 for the other groups). All relative fold changes are calculated in relation to the FM group.](pone.0218360.g005){#pone.0218360.g005}

Plasma proteome {#sec020}
---------------

We performed proteomic analysis on plasma sampled at day 30 from four individual fish from treatment FM, SBM, SBM200CU and FM200CU. In total, 286 salmon proteins were identified, and after filtering for proteins present in at least two of the four individuals per diet, 158 proteins were selected for further analyses ([S3 Table](#pone.0218360.s003){ref-type="supplementary-material"}). This criterion was used due to the variability among fish. A Venn diagram was built up with the 158 proteins showing the overlapping of proteins detected in the four dietary treatments ([Fig 6A](#pone.0218360.g006){ref-type="fig"}). There were 126 plasma proteins shared between the four groups. Moreover, each dietary treatment presented unique proteins except for diet SBM200CU (D6) ([Fig 6B](#pone.0218360.g006){ref-type="fig"}). The five unique proteins present in D1 (FM) were creatine kinase, lymphocyte cytosolic protein 2, histone H3, kininogen-1 and electron transfer flavoprotein alpha polypeptide. While in D2 (SBM), we detected three unique proteins: fatty acid-binding protein intestinal, transketolase and 14-3-3 beta/alph-1 protein. We did not detect unique proteins in D6 (SBM200CU), whereas in D7 (FM200CU) we found five unique proteins: GMP/IMP nucleotidase, hemoglobin subunit alpha, beta-globin, flavin reductase and L-lactate dehydrogenase.

![Common and unique proteins expressed in plasma of salmon fed different diets.\
(**A**) Venn-diagram showing the overlap between plasma protein sets detected across the four diet groups FM (D1), SBM (D2), SBM200CU (D6) and FM200CU (D7). (**B**) Unique proteins expressed in each dietary group.](pone.0218360.g006){#pone.0218360.g006}

In order to study the relative expression of proteins, we generated volcano plots comparing each dietary treatment to the control ([S3 Fig](#pone.0218360.s006){ref-type="supplementary-material"}). We observed that SBM induced the differential expression of nine proteins compared to the control diet (D1:FM), while diets containing yeast (200CU) show twelve and ten proteins respectively (SBM200CU, FM200CU) compared to the control diet ([Table 2](#pone.0218360.t002){ref-type="table"}).

10.1371/journal.pone.0218360.t002

###### Significant proteins compared to control diet.

Relative expression of plasma proteins compared to the control, p-value threshold 0.05.

![](pone.0218360.t002){#pone.0218360.t002g}

  --------------------- -------------------------------------------------- ----------------- -------------- ---------------
  **FM v/s SBM**        **Protein name**                                   **Fold Change**   **log2(FC)**   ***p*-value**
  C0HAL2                Elongation factor 1-alpha                          189.36            7.565          2.17E-13
  B5X5I8                Profilin                                           0.24669           -2.0192        0.023289
  C0H808                Tubulin beta chain                                 4.0217            2.0078         0.02352
  B5DG39                L-lactate dehydrogenase                            0.25567           -1.9677        0.024172
  B5X1J1                72 kDa type IV collagenase precursor               0.097995          -3.3511        0.028933
  C0PU02                Periostin                                          0.27034           -1.8872        0.043629
  B5DGM6                Adenylate kinase isoenzyme 1                       0.28582           -1.8068        0.046312
  Q98SJ9                Glycerol-3-phosphate dehydrogenase \[NAD(+)\]      0.31016           -1.6889        0.06348
  C1BX66                Kininogen-1                                        104.54            6.7079         0.095789
  **FM v/s SBM200CU**   **Protein name**                                   **Fold Change**   **log2(FC)**   ***p*-value**
  C0H808                Tubulin beta chain                                 17116             14.063         3.29E-15
  B5X1J1                72 kDa type IV collagenase precursor               0.076752          -3.7037        0.002394
  B5DG39                L-lactate dehydrogenase                            0.24712           -2.0167        0.02386
  B5RI57                Electron-transfer-flavoprotein alpha polypeptide   12192             13.574         0.023921
  B9ENN5                Complement C1q-like protein 4                      0.24833           -2.0097        0.023926
  C0HAL2                Elongation factor 1-alpha                          4.026             0.023934       0.023934
  C0HBQ3                Lymphocyte cytosolic protein 2                     13144             13.682         0.023995
  B5DG72                Phosphoglucomutase-1                               0.25169           -1.9903        0.024093
  B5XGT3                Lipocalin                                          3.9621            1.9863         0.024132
  B5X0R1                Complement component C7 precursor                  3.0761            1.6211         0.024173
  U5KQR2                Heat shock protein 90-beta 2                       3.2683            1.7086         0.034988
  C1BX66                Kininogen-1                                        9560.9            13.223         0.03771
  **FM v/s FM200CU**    **Protein name**                                   **Fold Change**   **log2(FC)**   ***p*-value**
  U5KQR2                Heat shock protein 90-beta 2                       144.16            7.1715         0.000177
  B5X1J1                72 kDa type IV collagenase precursor               0.077739          -3.6852        0.00245
  A0A085U717            GMP/IMP nucleotidase                               0.24972           -2.0016        0.02365
  B5RI57                Electron-transfer-flavoprotein alpha polypeptide   135.16            7.0785         0.023767
  C0HBQ3                Lymphocyte cytosolic protein 2                     145.5             7.1849         0.023813
  B5DG39                L-lactate dehydrogenase                            0.25203           -1.9883        0.023831
  C0HAI2                L-lactate dehydrogenase                            0.0075714         -7.0452        0.023863
  C0H808                Tubulin beta chain                                 3.9253            1.9728         0.024106
  B9ENC8                Transgelin                                         0.25797           -1.9547        0.024391
  B5DGM6                Adenylate kinase isoenzyme 1                       0.27851           -1.8442        0.045085
  --------------------- -------------------------------------------------- ----------------- -------------- ---------------

Discussion {#sec021}
==========

Research on the effects of nutrition on fish health and disease has mainly focused on intestinal local immune responses rather than evaluating overall health impact. Therefore, the present study used an integrated approach to achieve a better understanding of the effect of feeding inactive dry *C*. *utilis* yeast, SBM and increasing levels of *C*. *utilis* yeast to Atlantic salmon in presence of SBMIE. Herein, we discuss how both local changes in the DI, including morphology, immune cell profile and gene expression, and systemic changes in the plasma proteome could reflect challenges posed by dietary treatments.

A previous study has shown that there were no significant negative effects on feed intake, specific growth rate or feed conversion ratio when up to 30% *C*. *utilis* was included in the diet for salmon \[[@pone.0218360.ref004]\], but DI morphology was not assessed. A study where parr where fed 200 g/kg *C*. *utilis* with FM showed that this diet combination did not alter the DI morphology when compared with FM control diet \[[@pone.0218360.ref031]\]. The present study is the first to demonstrate that FM200CU diet maintains a DI morphology similar to the FM based control diet in sea-water adapted farmed salmon. Furthermore, FM200CU presented a similar T-cell population profile in the DI compared with the control FM group, indicating no stimulation of the local T-cell population when SBMIE was not present. No significant alterations in mRNA expression further support the assumption that FM200CU does not impose any local effect in a normal DI.

On the other hand, it is widely known that SBM induces inflammatory changes in the DI morphology, and the local immune response of the DI to SBM has been described as a T-cell mediated inflammatory response \[[@pone.0218360.ref009], [@pone.0218360.ref032]\]. At d 30, the SBM, SBM25CU and SBM200CU groups had increased CD3ε and CD8α cell populations in the DI, which is consistent with this finding. The CD3ε- and CD8α-lymphocytes were mainly confined to the basal part of the DI epithelium with only a few CD3ε-labelled cells scattered in the lamina propria adjacent to stratum compactum. However, Bakke McKellep *et al*. \[[@pone.0218360.ref032]\] reported that lamina propria adjacent to stratum compactum and stroma of complex folds were rich in CD3ε-labelled cells in DI presenting with SBMIE. The CD3ε- and CD8α related observations might imply that the SBM used in these studies differed in immunostimulatory properties.

Interaction between *C*. *utilis* and SBM has been described by Grammes *et al*. where feeding 200 g/kg *C*. *utilis* together with SBM (200 g/ kg) prevented SBMIE development in salmon \[[@pone.0218360.ref013]\]. In our study, the severity of SBMIE in fish fed the highest inclusion levels of *C*. *utilis* (i.e. SBM100CU and SBM200CU) in combination with SBM was similar to that of fish fed the SBM diet. Adding lower levels of *C*. *utilis* to SBM diets (i.e. SBM25CU and SBM50CU) resulted in a large variation within the groups, ranging from normal morphology to moderate SBMIE. However, there was a decreased presence of CD8α-cell population in the SBM25CU group compared with the SBM group indicating that *C*. *utilis* has an immunomodulating effect locally in the DI when included at a low level in the SBM diet. Thus, partial prevention of SBMIE occurred only with lower inclusion levels of *C*. *utilis* which might differ with the previous work. This inconsistency could be due to differences in the degree of bioactivity of the *C*. *utilis* yeast, or in the ANF content of the SBM, and/or the experimental conditions. For example, Øverland and Skrede \[[@pone.0218360.ref011]\] have speculated that the inconsistent effect of yeast on host immunity can be attributed to yeast strain, fermentation conditions, and downstream processing when manufactured. Furthermore, Miadoková *et al*. concluded in their study that the biological activity of glucomannan isolated from *C*. *utilis* is dependent on the combined application with other biologically active compounds \[[@pone.0218360.ref033]\]. Also, the host itself can be the reason for this inconsistency as it has been demonstrated that the severity of SBMIE can differ between strains of rainbow trout \[[@pone.0218360.ref034]\]. Additionally, the composition of the diet can induce variation in both the mucosa-associated and digesta-associated microbiota in Atlantic salmon \[[@pone.0218360.ref035], [@pone.0218360.ref036]\].

The mRNA expression profile of *aqp8* gene in the DI in the diet groups (FM, FM200CU, SBM, SBM200CU) indicates an association of *aqp8* with the resulting DI morphological and immune cell responses to nutritional challenges observed in this study. Our results confirm previous findings showing suppression of *aqp8* gene expression in intestinal inflammatory processes in salmon such as SBMIE \[[@pone.0218360.ref013], [@pone.0218360.ref037]\]. The relation between *aqp8* expression and inflammation is consistent with cell-based studies showing that reduced *aqp8* expression is linked to increased oxidative cell stress damage \[[@pone.0218360.ref038]\] and implying that *aqp8* is a key player in the maintenance of redox cellular status. Intestinal inflammation in salmon resulting from SBM has been shown to have wider systemic effects in plasma including increased insulin levels \[[@pone.0218360.ref039]\] and reduced plasma bile salt and cholesterol levels \[[@pone.0218360.ref040]\]. In the present study, we found three proteins uniquely expressed in the SBM group; fatty acid-binding protein intestinal, transketolase and 14-3-3 protein beta. Salmonids fed SBM often present with reduced lipid digestibility \[[@pone.0218360.ref053]\], which can explain the presence of fatty acid-binding proteins in the plasma, due to tissue damage in the distal intestine.

The shift in diet at d 30 of the experiment showed that the developed enteritis observed in the DI of fish fed either SBM alone or in combination with *C*. *utilis* was resolved after feeding FM diet for 7 d. It is also important to point out that the degree of SBMIE was reduced from moderate to mild after 7 d feeding FM200CU diet to those fish fed SBM diet for 30 d. It can be suggested that all fish would have returned to a normal state if the experiment had lasted longer. Additionally, feeding FM200CU for 30 days prior to a diet shift to SBM did not prevent development of enteritis in the DI.

The present study revealed that dietary challenge induced the differential expression of specific proteins of the proteome but did not demonstrate a direct link to the local changes in the DI. This might have several explanations, such as sampling point, high variability among individuals and difficulty to measure individual feed intake. It should be noted that there is a lack of ideal biomarkers in gastrointestinal diseases in humans \[[@pone.0218360.ref018]\], such as inflammatory bowel diseases (IBDs), which further elucidates the difficulties of finding changes in the plasma proteome that can be directly linked to local inflammation or immunomodulation of the intestine. Nevertheless, there were specific proteins that were significantly expressed in our study that are of interest. We found that in the SBM group, there is an increased expression of periostin when compared with FM group. Periostin is a matricellular protein, belonging to the fasciclin family, that are also defined as an extracellular matrix protein that binds to cell-surface receptors \[[@pone.0218360.ref041]\]. This protein is an emerging biomarker reflecting type 2 inflammation in allergic diseases in humans \[[@pone.0218360.ref042]\], and it has also been suggested that periostin mediates intestinal inflammation in mice \[[@pone.0218360.ref043]\] and promote tumorigenesis in humans \[[@pone.0218360.ref044]\]. In both SBM and SBM200CU diet the expression of kininogen-1 is decreased. The plasma kallikrein-kinin system (KKS) has been shown to be activated in patients suffering with active IBDs where the high-molecular-weight kininogen and prekallikrein were significantly decreased in plasma assuming an increased KKS activation/consumption \[[@pone.0218360.ref045], [@pone.0218360.ref046]\]. Lipocalin is produced in the intestine by intestinal epithelial cells and is upregulated in presence of intestinal inflammation, and therefore is an attractive a biomarker for IBDs in humans \[[@pone.0218360.ref047], [@pone.0218360.ref048]\]. In our study, lipocalin was significantly decreased in plasma of the SBM200CU group. Additionally, L-lactate dehydrogenase was found to be differentially expressed in all dietary treatments, which would suggest that further experiments investigating the activity of this protein could be useful to elucidate the mechanism of action of yeast in salmon. L-lactate dehydrogenase, which catalyzes the conversion of lactate to pyruvate, consequently its activity increases under periods of muscular damage. Therefore, some authors suggest that the levels of lactate dehydrogenase in blood can be used as a diagnostic tool to predict cardiomyopathy syndrome or skeletal muscle inflammation on salmon, however the plasma levels do not correlate consistently with histological scores \[[@pone.0218360.ref049]\].

Differences between the plasma protein profiles of fish receiving SBM diets (SBM and SBM200CU) and FM diet were expected, as systemic changes may accompany a local tissue inflammation, thus plasma protein profiling could be a useful tool to determine the association between systemic response and outcomes of nutritional local challenges. However, the overall changes in the plasma proteome may be due to specific components in the diets (e.g. immunomodulating compounds of *C*. *utilis*) rather than local responses towards inflammation. Although obvious differences between SBM and SBM200CU were not manifested at morphological levels, we show that the SBM200CU group had a significant differential expression of complement C1q-like protein 4 and complement component C7 precursor in the plasma when compared with control group (shown in [Table 2](#pone.0218360.t002){ref-type="table"}). Complement factors are part of the innate immune system that enhance the ability of antibodies and phagocytic cells to clear microbes and damaged cells and promote inflammation. C7 is a precursor protein that, together with four other proteins, forms the membrane attack complex (MAC) of complement \[[@pone.0218360.ref050]\]. Complement C1q-like protein 4 has a C1q-like domain, similar to domains in C1 complex, and is assumed to take part in controlling aspects of inflammation, adaptive immunity and energy homeostasis \[[@pone.0218360.ref051]\]. Non-specific cellular and non-cellular immune responses have been reported when microbial ingredients have been included in fish diets \[[@pone.0218360.ref052], [@pone.0218360.ref053]\], and increase in complement activation in serum has been demonstrated in sea bass, jian carp and rainbow trout fed diets containing β-glucans \[[@pone.0218360.ref054]--[@pone.0218360.ref057]\]. Also, increased activities of complement in plasma of Atlantic salmon receiving an intraperitoneal injection of glucans from *Saccharomyces cerevisiae* have been demonstrated \[[@pone.0218360.ref058]\]. Interestingly, complement proteins were not differentially expressed in SBM or FM200CU groups, which suggests that the combination of SBM and yeast might trigger a different immune response than yeast alone. Additionally, heat shock protein 90, which is involved in the response to stress \[[@pone.0218360.ref059]\], was differentially expressed in the diets containing yeast (SBM200CU and FM200CU), but not in the group fed SBM alone. Currently, the effect of heat shock proteins on fish health is not clear, however our results showed that the inclusion of yeast in diets reduces its expression, which might be due to the immunomodulatory components present in the membrane of yeast.

This study combined traditional methods of assessing local tissue responses with plasma proteomic analysis in order to achieve a better understanding of the effects of nutrition on fish health and disease, and to identify systemic protein profiles in response to the dietary treatments. The inclusion of 200 g/kg of *C*. *utilis* yeast to a FM based diet (i.e. FM200CU) as a novel protein source with potential functional properties produced similar DI morphology, immune cell population and gene expression profiles, compared with a FM based control. Feeding the SBM diet induced SBMIE while feeding lower inclusion levels of *C*. *utilis* in combination with SBM (i.e. SBM25CU and SBM50CU) reduced the severity of SBMIE. Interestingly, higher inclusion levels of *C*. *utilis* yeast (i.e. SBM100CU and SBM200CU) did not show any significant protection against SBMIE, which is in contrast to a previous study that has shown protection. Changes in the plasma proteomics between groups with different dietary challenges were observed, however, their potential for the identification biomarkers for health or disease is yet to be elucidated. The absence of any clear alterations of expression of proteins within specific biological pathways would indicate that the effects due to diets were mainly restricted to local tissue responses.

In conclusion, our results suggest that C. utilis does not alter intestinal morphology or induce major changes in plasma proteome, and thus could be a high-quality alternative protein source with potential functional properties in diets for Atlantic salmon.
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###### Chemical composition (g kg^-1^) of dry *Candida utilis* biomass.

(DOCX)

###### 

Click here for additional data file.

###### Primers used in qPCR analysis.

(DOCX)

###### 

Click here for additional data file.

###### 158 proteins identified and their quantitative values.

(XLS)

###### 

Click here for additional data file.

###### Morphometric measurement.

Red line indicates the measurement of fold height from the tip of the simple fold to the stratum compactum. The yellow line indicates the fold area including the simple fold and the lamina propria adjacent to the stratum compactum.

(JPG)

###### 

Click here for additional data file.

###### Histology.

Representative histomorphological images from hematoxylin and eosin-stained sections of the distal intestine of Atlantic salmon fed control FM diet **(A)** and experimental diets **(B-F)**. Normal morphology was seen in FM **(A)** and FM200CU **(B)** groups. Moderate changes associated with SBMIE was observed in the distal intestine of salmon fed SBM (**C**: SBM25CU, **E**: SBM200CU, **F**: SBM). Low inclusion of *C*. *utilis* to the SBM diet showed variation within the group ranging from individuals showing little changes (**D**: SBM25CU) to individuals with moderate changes in DI morphology (**C**: SBM25CU). All images are captured at 4x magnification with a scale bar (100μm).

(TIF)

###### 

Click here for additional data file.

###### Volcano plot.

Volcano plots showing the relative expression of plasma proteins from fish fed SBM (A), SBM200CU (B) or FM200CU (C) compared to the control (FM). ANOVA plot with p-value threshold 0.05.

(TIF)

###### 

Click here for additional data file.
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Major concerns:

The experimental design seems carefully planned and complex, with many groups and variables. However, not all groups were used for all analyses and there is no explanation why. For example, it is stated that low doses partially prevent SBMIE, but these groups were not included in the gene expression or proteomic analyses. In addition, an explanation of the different effect that low and high levels of C. utilis have on inflammation should be included.

The discussion seems to focus on randomly selected proteins. There is the description of the function of some of these proteins but I fail to see the point and relevance in this particular study. In my opinion, the whole discussion should be revised to follow a particular relevance point regarding this research, animal model and application.

Other comments:

L71: This sentence looks weird. Maybe the authors meant: "...an inactive dry Candida utilis strain was used..." or "... an inactive dry yeast strain of Candida utilis... ".

L108: Vaccinated against?

When mentioning average body weight values the error should be included. For instance, L116.

L123: The feeding strategy was changed to what? In general, the experimental design is not clearly explained and even though there is a nice explanatory figure the text should be more clear.

L200: The amount of tissue used for RNA isolation should be stated.

L215: The concentration of the primers should be stated. Also, in the supplementary figure of the primer sequences the symbol for GDPH is GADPH, please unify the nomenclature.

L253: I think a reference to the salmon proteome should appear here.

L269: Why a series of PCA? Were several analyses performed? If so, they should be described. Also, verify the use of analyses instead of analysis for the plural.

L289: The average initial and final weight are mentioned (again I'm missing the errors), but there is no comparison among groups. Were there differences? Maybe a table should be included with the group values?

L303: "described in detail below" (remove the "ed")

L293: section Histology: A panel of pictures showing the most significant changes (like the ones described in L308-312) would be nice. Also, how do the authors know exactly which cell types are present (L311-312) without specific markers? Some of these cells are difficult to identify in intestinal sections.

L323-324: Why where those groups excluded from the figure?

L366-367: The difference mentioned here is not represented in the figure, in fact, regarding the figure statistics these groups were not different in this parameter.

L387: The sudden change in nomenclature does not simplify the reading of the data, it actually complicates it. The nomenclature should be maintained along the manuscript (including the figures). In addition, why were the groups with low yeast dose excluded from this analysis? This should be explained in detail, particularly because the work concludes that the low doses are the ones having more positive effects but there are no results about them in this part of the study.

L403 and Fig6C: This heatmap seems to show differential expression values. If this is correlation I don't understand against what each molecule is correlated. Please revise these results and explanations.

L409: "Analyses were carried out first with...." Why first? Was there a second analysis?

L445: These inconsistencies should be further explained.

L473: Delete DI.

L473-475: The statements about the role of aqp8 in homoeostasis should be further supported.

L489-492: I do not see the point of mentioning these particular roles of MHCI here. Maybe the authors are trying to make a point I do not understand.

L494: One study or several? If one, change for "A previous study". Otherwise use plural.

L509: Downregulation in which tissue?

Figure 3: Scale bars should be added to the pictures.

Figure 5: The fold change is relative to what?

Reviewer \#2: Review of PONE-D-19-15096 " Candida utilis yeast as a functional protein source for Atlantic salmon (Salmo salar L.): Local intestinal tissue and plasma proteome responses".

This manuscript describes the effects of using a yeast strain as a functional protein source to boost gut health in fish at risk of intestinal enteritis when fed soy bean-based meal. The study tackles a highly relevant problem and is generally very well written and clear. Overall, this study will provide an important contribution to the field and fit well into the PLoS one journal. Below I provide some general and more specific comments to help the authors improve the manuscript for publication.

General comments

I want to applaud the authors for performing such a holistic analysis opposed to using just one single method. This is very much needed and sets a great standard for future studies.

However, what I miss a little is an attempt to better link all the data sets together in a biological way. Could simply be through discussing results, but in a way to e.g. link the genes tested for expression responses with the proteins analyses all the way to the tissue histological data. Maybe add a conceptual figure with the entire path from DNA -\> RNA -\> proteins -\> tissues and the highlight where you have generated data and results. As is, the different data types are treated quite independently and in a somewhat random order.

For example, the discussion on lines 467-469 represents a good example of how gene expression data is integrated with insights from histology and immune response data.

Contrary, on lines 484-488 is an example where the protein plasma data is mainly discussed in isolation, whereas it would benefit from a stronger focus on the underling biological interactions with e.g. gene expression, histology and immune response data.

Specific comments

L. 108: What was the fish vaccinated against? Was it a standard vaccination program or inly for a specific disease? Pease specify.

L. 158: Which and how many fish were used for this immunohistochemistry analysis? Was it the same 8 fish as above or new ones? Please specify.

L. 224: Do you mean "... as index" instead of "... an index"?

L. 229 + 231 + throughout: Be consistent whether or not you add a space between the degree symbol and "C" when listing temperature values.

L. 253: Please provide a reference for the salmon proteome reference database.

L. 262-263: Can you clarify this description as it sounds like all individuals are already part of \"a cluster\" when you begin. So, when does the model know to end the analysis? Is it e.g. trying to minimise the number of clusters based on some preset value? This remains unclear as currently written.

L. 275: Add space before "\[31\]".

L. 388-389: It is not clear to me how this \"simplifies\" except using fewer letters. The figures have plenty of space to write out the FM and SBM names respectively, and these are much more informative than having to cross read between the text here and the figure to know what D1-D4 represents. I would prefer to just keep the FM and SBM based names in the figures as well. Same for Fig. 7.

L. 438-444: Could this maybe also be due to individual responses among fish, and that these responses are partly controlled by the different genotypes among individuals? For example, if host genotype selects for different gut-microbiota communities, one could speculate that such different gut environments will differ in their ability to respond to the provided C. utilis strains? I agree this is very speculative, but the explanation do warrant mention as opposed to only focusing on how external parameters could explain the observed variation in gut responses; which seems to be the standard way of interpreting these types of gut data.

L. 503: re-write to \"proteins with significant over expression in \... \". The proteins themselves are not significant, it is their expression level that is.

Figure 2: Please add labels for all Y axes.

Figure 3: Please clarify the different colors in the figure images. Are CD8 positive cells the purple colored ones? Or are both CD3 and CD8 colored brown? If so, what are the purple stains?

Figure 4: Discuss whether the low sample size (n=7) may cause type-2 errors for the non-significant comparisons?

Figure 5: Add both a and b letters between the two diet categories in the plots where there are significant differences.

Also, same concern as for figure 4 about regarding lack of statistical power with the relatively low sample sizes. Was any prior power analyses performed to inform the used sample sizes? There are some differences in e.g. plot C that could potentially be significant with more statistical power, which could for example be obtained through an increased sample size.

Reviewer \#3: General Impressions:

In this manuscript, the authors performed a feeding trial on Atlantic salmon in which fish were fed fish meal or soybean meal-based diets that were supplemented with varying amounts of Canadis utilis yeast. Changes in intestinal morphology and the plasma proteome of the fish were monitored at several points in the study in order to monitor both intestinal and systemic effects of the different diets.

Overall, the experimental design appears valid and the data collection and analysis of the histological data is appropriate. However, in the eyes of this reviewer, the analysis of the plasma proteomics data could be improved to allow for more meaningful interpretation of the data. The current methodology does not provide significant evidence that the observed changes in the plasma proteome are related to the differences in diet. However, after the authors address the following comments, the manuscript would likely be suitable for publication.

Major Comments:

• The authors relied primarily on Spearman's correlation coefficients to identify proteins of interest from the plasma proteomics data. Therefore, the authors are essentially looking for cases where protein abundances do or do not correlate across the different diets. However, since there is a clear control in the experiment (fish meal-based diet), it seems that comparing all protein abundance to that control would be more informative. Then, emphasis would be placed on proteins that have 'abnormal' expression relative to the fishmeal fed fish. This would also allow for volcano plots to be generated and included in the manuscript, which would aid reader understanding.

• Further description of how the quantitative values used in the proteomics analysis is needed. It appears that precursor abundance (from the MS1 scans) were used, but that is not explicitly stated. If that is the case, was peak intensity or peak area used? Also, was the 'match between runs' feature enabled in MaxQuant?

• A table showing all of the proteins identified in the plasma analyses and their quantitative values should be provided in the supplement. Ideally, fold change values should also be included. It's possible that such a table was uploaded to PRIDE, but the PXD number provided does not bring up any results when searched. This is likely because the dataset has not been publicly released but the login info should be provided to reviewers.

• It is concerning that the fishmeal-based and soybean-based diets don't cluster in either the heatmap or the PCA plots. It seems likely that such large differences in the feed would causes systemic changes in the blood which would lead to high correlation between the D1 and D7 samples, but that was not observed. This suggests that either the analysis method was flawed, or that individual variation was too large in order to adequately detect differences from the feed.

• Although this reviewer is not well versed in the VIP method used here, it seems that this technique is likely to put too much emphasis on proteins that are correlated purely by chance. Further justification of this technique should be included, or the analyses should be removed.

• It would be helpful if the reviewers included a few representative images of the changes in morphology observed between the groups that are summarized in Fig. 2. This could be included as an additional supplemental figure.

Minor Comments:

• L252: The fragment ion tolerance used here is much too large for orbitrap data. A tolerance of 0.02 Da would be more appropriate.

• L253: Where was the salmon proteome database derived from? Was it a public repository such as uniprot? If so, when was it downloaded?

• L316: No data is shown in this figure where SBM + C. utilis was fed first, followed by FM. This sentence says otherwise.

• Fig. 4 caption -- L371: What is meant hear by 'data are expressed as mean � SD for each individual'? Isn't each point just representative of the mean for each fish? This should be clarified.

• L407-408: It doesn't make sense to say that proteins 'belong' to a specific domain. Please revise.

• Fig. 7 caption -- L424: What do the colors in panel C represent? Also, why are proteins with VIP scores \< 2 included here?

• L473: Remove 'DI.'

• L476: Change considering to considered.
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Reviewer \#1: The present work studies how the addition of C. utilis in soybean meal based diets impacts or reverts the changes induced when compared to a control fishmeal based diet. The results show that low levels of yeast reduced the severity of the enteritis caused by soybean meal based diets and C. utilis is proposed as an alternative protein source in functional diets for Atlantic salmon. In my opinion, this is a very attractive and complete study that combines different techniques in order to evaluate Atlantic salmon intestinal health. However, I have some comments and concerns that I believe should be addressed before considering this manuscript for publication.

Major concerns:

The experimental design seems carefully planned and complex, with many groups and variables. However, not all groups were used for all analyses and there is no explanation why. For example, it is stated that low doses partially prevent SBMIE, but these groups were not included in the gene expression or proteomic analyses. In addition, an explanation of the different effect that low and high levels of C. utilis have on inflammation should be included.

The discussion seems to focus on randomly selected proteins. There is the description of the function of some of these proteins but I fail to see the point and relevance in this particular study. In my opinion, the whole discussion should be revised to follow a particular relevance point regarding this research, animal model and application.

Unfortunately, we could not analyze all samples in all analyses. Based on earlier experience with microbial ingredients, we assumed that the highest concentratiosn of CU would have the most effect when added to SBM based diet. Thus e.g., in the proteomic analyses, only FM (D1), SBM (D2), SBM200CU (D6) and FM200CU (D7) groups were subjected to analyses. In other analyses, we have included higher number of samples/dietary treatments.

We have revised and re-arranged large parts of the discussion.

Other comments:

L71: This sentence looks weird. Maybe the authors meant: "...an inactive dry Candida utilis strain was used..." or "... an inactive dry yeast strain of Candida utilis... ".

Changed to: "... an inactive dry yeast strain of Candida utilis..."

L108: Vaccinated against?

Farmed Atlantic salmon in Norway are routinely vaccinated as pre-smolts against a number of diseases. In this case, the Aquavac PD7 was used (contains vaccine against bacterial furunculosis, vibriosis, cold water vibriosis, winter ulcer) and viral (infectious pancreatic necrosis (IPN), pancreas disease, infectious salmon anaemia (ISA)) diseases.

We have added this, thus the sentence now reads: "Vaccinated salmon (Aquavac PD7, MSD Animal Health, Bergen, Norway) were acquired from...".

When mentioning average body weight values the error should be included. For instance, L116.

To avoid too much stress for the fishes at the start of the experiment, it is common to register bulk weigh of all fish per tank. Thus, in this experiment, we have only the bulk starting weight of the 20 individuals per tank. We can therefore only give an average initial body weight (526 g) withour the error.

L123: The feeding strategy was changed to what? In general, the experimental design is not clearly explained and even though there is a nice explanatory figure the text should be more clear.

A paragraph was added in order to make the feeding strategy more clear:

Following the acclimation period, each experimental diet was randomly allocated to the fish tanks (two tanks/diet) and fed for 30 days (period 1) as described above. After 30 days, the feeding strategy were changed and new diets were fed for 7 days (period 2). As a control, one fish group received FM throughout the experiment. To assess whether C. utilis were able to counteract enteritis induced by SBM, four fish groups received SBM diets combined with different inclusions levels of CU (i.e. SBM25CU, SBM50CU, SBM100CU, SBM200CU) in period 1. One fish group received FM200CU in period 1 to evaluate if C. utilis in combination with FM alone would have an effect on the DI. In period 2, the ability of C. utilis to prevent SBMIE was assessed as the diet was changed to SBM in this group. Finally, three fish groups were fed SBM diet to induce SBMIE in period 1, and in period 2 the diets were changed to either FM, FM200CU and SBM200CU to evaluate if these diets were able to reverse SBMIE. The feeding strategy is illustrated in Fig. 1.

Subsequently L132-135 were changed to:

At each sampling point (0, 7, 30 and 37 days), 8 fish per diet (4 fish per tank) were randomly selected and anaesthetized by immersion in 60 mg/l of tricaine methanesulfonate (MS-222, Sigma-Aldrich, MO, USA) and subsequently euthanized by a sharp blow to the head.

L200: The amount of tissue used for RNA isolation should be stated.

The sentence have been changed to: A small piece of DI tissue (approximately 0.5 cm) from FM, FM200CU, SBM and SBM200CU diet groups (8 fish/diet) at day 30 were subject to gene expression analysis.

L215: The concentration of the primers should be stated. Also, in the supplementary figure of the primer sequences the symbol for GDPH is GADPH, please unify the nomenclature.

The primer concentration has been added.

GDPH had been changed to GAPDH

L253: I think a reference to the salmon proteome should appear here.

The salmon proteome was added to the main text (<https://www.uniprot.org/proteomes/?query=taxonomy:8030>)

L269: Why a series of PCA? Were several analyses performed? If so, they should be described. Also, verify the use of analyses instead of analysis for the plural.

The description of the analysis was edited for a better understanding.

"An initial PCA was used as an unsupervised method to find the directions of maximum covariance among FM, SBM, SBM200CU and FM200CU was performed using the prcomp package in R to see the distribution of the proteins present in all the groups".

L289: The average initial and final weight are mentioned (again I'm missing the errors), but there is no comparison among groups. Were there differences? Maybe a table should be included with the group values?

This was not a growth experiment. But to be sure that fish in all dietary treatments were eating, and growing, the feed intake was registered. Fish weights were only registered as bulk weight per tank at the start of the experiment, and as individual body weights for the fishes that were sampled in weeks 0, 1, 4 (period 1) and 5 (period 2). To avoid unnecessary disturbance, the fish left in the tank at the different time points were not taken out for weighing. Thus at the end of the experiment, there were very few fish left per tank. We feel that growth responses should therefore not be presented in a table.

However, there were no significant differences due to dietary treatment when it comes to both feed intake nor growth. Thus we have added "nor growth rate" to make it more clear to the reader. The new sentence reads: "All groups of fish accepted their allocated diets and no significant differences were found in feed intake nor growth rate among dietary treatment".

L303: "described in detail below" (remove the "ed")

The authors don't think it will be correct to remove "ed" in this context and want to leave it as it is.

L293: section Histology: A panel of pictures showing the most significant changes (like the ones described in L308-312) would be nice. Also, how do the authors know exactly which cell types are present (L311-312) without specific markers? Some of these cells are difficult to identify in intestinal sections.

A panel of pictures (S2 Fig.) is included showing the overall differences between the groups but also variation within the SBM25 group.

Yes, it is indeed difficult to identify specific leucocytes in intestinal sections but not impossible. There was not made an effort to make a semi-quantitative assessment of the various cell types in the different diets, thus only the leucocytes that were in abundancy will be mentioned. Therefore, L309-312 will be reduced to: "There was an increased presence of connective tissue in the lamina propria and the increased infiltration of leucocytes consisted mainly of eosinophilic granule cells and to a lesser extent of lymphocytes."

L323-324: Why where those groups excluded from the figure?

L323-324: these two SBM groups were similar with the SBM group presented in the figure and therefore omitted from the figure to generate equal groups. The individuals from both of these groups are now included making the SBM group n = 23.

L366-367: The difference mentioned here is not represented in the figure, in fact, regarding the figure statistics these groups were not different in this parameter.

The data for morphometric measurements and CD-densities were analyzed in JMP, but the figure was made in GraphPad. Running wrong statistical analysis in GraphPad resulted in wrong statistical differences expressed as "a", "b" and "c" in the figure, and consequently, the wrong figure was submitted. The significant differences were presented in the result section and discussed in the text according to the statistics that were originally run in JMP. To simplify the text, the data set has been rerun in GraphPad and the correct figure has been submitted in the revised version.

L240-247 have been updated to:

"Non-parametric data from the histological evaluation were analyzed by Kruskal-Wallis followed by post hoc Dunn's test with a comparison of mean rank. Shapiro-Wilk normality test was used to test the normal distribution of the data from morphometric analyses and T-cell density, and further were analyzed by one-way ANOVA followed by Tukey's multiple comparisons test. Morphometric analyses and T-cell density analyses were performed at the individual level using the mean of measurements of between 2-6 simple folds per fish. Results of qPCR (means ± standard deviations) were analyzed using One-way ANOVA with Dunnett\`s multiple comparison test (a \< 0.0001). These analyses were performed in GraphPad Prism, version 7.00 and 8.0.1 (GraphPad Software Inc., San Diego, CA, USA).

L387: The sudden change in nomenclature does not simplify the reading of the data, it actually complicates it. The nomenclature should be maintained along the manuscript (including the figures). In addition, why were the groups with low yeast dose excluded from this analysis? This should be explained in detail, particularly because the work concludes that the low doses are the ones having more positive effects but there are no results about them in this part of the study.

Besides the explanation included in the main text, we included a extra legend on Fig 6 and 7, referring to the different groups and its nomenclature. The aim of the proteomic analysis was to identify potential biomarkers or protein express uniquely on the SBM induced enteritis groups. Therefore, we choose the extreme groups. Nevertheless, we did not observe unique proteins which can be used as markers. Then we focus on the proteins that were differently expressed, but present in all the groups. We agree with the Reviewers at it could be very interesting to run proteomic analysis considering the low dose, it will be considered in our future trials.

L403 and Fig6C: This heatmap seems to show differential expression values. If this is correlation I don't understand against what each molecule is correlated. Please revise these results and explanations.

The heatmap was generated based on the pairwise comparisons across the four time points. As per your suggestion, to be simplified and easy for the audience to follow, we have re-analyzed and produced three heatmaps, with each diet treatment to the control (FM). The old heatmap figure is replaced with new heatmaps (Fig 6C).

L409: "Analyses were carried out first with...." Why first? Was there a second analysis?

The description of the analysis was edited as follow:

"PCA analysis was carried out first with all selected proteins across dietary groups, then PLS-DA multivariate analyses were performed to detect the proteins responsible for the differentiation between dietary groups (Fig 7D)."

L445: These inconsistencies should be further explained.

These inconsistencies have further been explained with:

Furthermore, Miadoková et al concluded in their study that the biological activity of glucomannan isolated form C. utilis dependent on the combined application with other biologically active compounds \[56\]. Also, the host itself can be the reason for this inconsistency. It has been demonstrated that the severity of SBMIE can differ between strains of rainbow trout \[57\], and that diet can induce variation in both the mucosa-associated and digesta-associated microbiota in Atlantic salmon \[58, 59\].

L473: Delete DI.

The discussion has been rewritten, thus this is not relevant in the new discussion.

L473-475: The statements about the role of aqp8 in homoeostasis should be further supported.

L473-475 has been removed as our data does not support this statement.

L489-492: I do not see the point of mentioning these particular roles of MHCI here. Maybe the authors are trying to make a point I do not understand.

This paragraph has been rewritten in the discussion.

L494: One study or several? If one, change for "A previous study". Otherwise use plural.

This line has been rewritten as part of the rearrangement of the discussion.

L509: Downregulation in which tissue?

In the study performed by Grammes et al, a downregulation of LYME mRNA was observed in DI. Our study indicate that in DI inflammation there are high plasma levels of LYME.

Figure 3: Scale bars should be added to the pictures.

Scale bars are added to the pictures

Figure 5: The fold change is relative to what?

The relative fold changes are calculated in relation to the FM group.

Reviewer \#2: Review of PONE-D-19-15096 " Candida utilis yeast as a functional protein source for Atlantic salmon (Salmo salar L.): Local intestinal tissue and plasma proteome responses".

This manuscript describes the effects of using a yeast strain as a functional protein source to boost gut health in fish at risk of intestinal enteritis when fed soy bean-based meal. The study tackles a highly relevant problem and is generally very well written and clear. Overall, this study will provide an important contribution to the field and fit well into the PLoS one journal. Below I provide some general and more specific comments to help the authors improve the manuscript for publication.

General comments

I want to applaud the authors for performing such a holistic analysis opposed to using just one single method. This is very much needed and sets a great standard for future studies.

However, what I miss a little is an attempt to better link all the data sets together in a biological way. Could simply be through discussing results, but in a way to e.g. link the genes tested for expression responses with the proteins analyses all the way to the tissue histological data. Maybe add a conceptual figure with the entire path from DNA -\> RNA -\> proteins -\> tissues and the highlight where you have generated data and results. As is, the different data types are treated quite independently and in a somewhat random order.

An attempt to link the data sets together in a biological way have been made in the rewritten discussion.

For example, the discussion on lines 467-469 represents a good example of how gene expression data is integrated with insights from histology and immune response data.

Contrary, on lines 484-488 is an example where the protein plasma data is mainly discussed in isolation, whereas it would benefit from a stronger focus on the underling biological interactions with e.g. gene expression, histology and immune response data.

We agree with the Reviewers. Therefore the discussion have been rewritten.

Specific comments

L. 108: What was the fish vaccinated against? Was it a standard vaccination program or inly for a specific disease? Pease specify.

Farmed Atlantic salmon in Norway are routinely vaccinated as pre-smolts against a number of diseases. In this case, the Aquavac PD7 was used by Sørsmolt AS.

We have added this information, thus the sentence now reads: "Vaccinated salmon (Aquavac PD7, MSD Animal Health, Bergen, Norway) were acquired from...".

L. 158: Which and how many fish were used for this immunohistochemistry analysis? Was it the same 8 fish as above or new ones? Please specify.

The same 8 fish from each diet group were used for histology, immunohistochemistry and qPCR. L158-159 has been changed in order to make this clearer:

Histological sections of DI from the fish sampled at day 30 (8 fish/diet), prepared as described above, was subjected for immunohistochemical analysis, and the following diet groups were included: FM, FM200CU, SBM, SBM25CU and SBM200CU.

L. 224: Do you mean "... as index" instead of "... an index"?

L224 changed to "... an index"

L. 229 + 231 + throughout: Be consistent whether or not you add a space between the degree symbol and "C" when listing temperature values.

When listing temperature values, all have been changed to °C with no space between degree symbol and "C".

L. 253: Please provide a reference for the salmon proteome reference database.

The salmon proteome as been included in material and method

L. 262-263: Can you clarify this description as it sounds like all individuals are already part of \"a cluster\" when you begin. So, when does the model know to end the analysis? Is it e.g. trying to minimise the number of clusters based on some preset value? This remains unclear as currently written.

We agree and the sentence have been modifies as follow:

"The clustering results are presented in the form of a heatmap, with levels of protein expression across the three dietary groups (SBM (D2), SBM200CU (D6) and FM200CU (D7) compared to the control FM (D1). Hierarchical clustering was performed with the hclust function in R package stat. UniprotKB database was used for functional annotation of the proteins."

L. 275: Add space before "\[31\]".

Space has been added before "\[31\]"

L. 388-389: It is not clear to me how this \"simplifies\" except using fewer letters. The figures have plenty of space to write out the FM and SBM names respectively, and these are much more informative than having to cross read between the text here and the figure to know what D1-D4 represents. I would prefer to just keep the FM and SBM based names in the figures as well. Same for Fig. 7.

Besides the explanation included in the main text, we included an extra table on Fig 6 and 7, referring to the different groups and its nomenclature.

L. 438-444: Could this maybe also be due to individual responses among fish, and that these responses are partly controlled by the different genotypes among individuals? For example, if host genotype selects for different gut-microbiota communities, one could speculate that such different gut environments will differ in their ability to respond to the provided C. utilis strains? I agree this is very speculative, but the explanation do warrant mention as opposed to only focusing on how external parameters could explain the observed variation in gut responses; which seems to be the standard way of interpreting these types of gut data.

This is a good point which have already been briefly mentioned/discussed in the following sentences in the manuscript:

"Also, the host itself can be the reason for this inconsistency. It has been demonstrated that the severity of SBMIE can differ between strains of rainbow trout (Venold 2012), and that diet can induce variation in both the mucosa-associated and digesta-associated microbiota in Atlantic salmon (Gajardo 2016, 2017)".

However, as we do not have the actual genotypes of these salmon (they were purchased from Sørsmolt AS), a further discussion of this point would be just speculation.

L. 503: re-write to \"proteins with significant over expression in \... \". The proteins themselves are not significant, it is their expression level that is.

This line has been rewritten as part of the rearrangement of the discussion.

Figure 2: Please add labels for all Y axes.

The label "Scale" is added for all Y axes.

Figure 3: Please clarify the different colors in the figure images. Are CD8 positive cells the purple colored ones? Or are both CD3 and CD8 colored brown? If so, what are the purple stains?

Color development of both CD3 and CD8 was performed by 3,3'-diaminobenzidine, therefore both CD3 and CD8 positive cells are labeled with brown color. As the detection of these cells were run in two different assays where specific antibody was applied, we can count positive CD3-labelled cells when antibody towards CD3 was applied and we can count positive CD8-labeled cells when antibody towards CD8 was applied. In both cases, the slide was counterstained with hematoxylin that gives a purple color in order to visualize to the structure of the rest of the intestinal mucosa.

Figure 4: Discuss whether the low sample size (n=7) may cause type-2 errors for the non-significant comparisons?

The sample size was in fact n=8, except for the SBM group, but we agree that this is indeed a low sample size. We would of course have preferred to have a higher number of fish, but the experimental set-up, number of available tanks and limit of biomass in each tank did not allow for a higher number. A larger sample size, e.g., by one more tank per dietary treatment (i.e., 3 tanks instead of 2) could have strengthened our results. However, since we have measured/analyzed many different parameters in the same individual fish, and these analyses do support each other, we still feel confident with these results.

Figure 5: Add both a and b letters between the two diet categories in the plots where there are significant differences.

Letter a and b were added between the two diets where there are a significant differences

Also, same concern as for figure 4 about regarding lack of statistical power with the relatively low sample sizes. Was any prior power analyses performed to inform the used sample sizes? There are some differences in e.g. plot C that could potentially be significant with more statistical power, which could for example be obtained through an increased sample size.

Unfortunately, the wrong figure was submitted. The correct figure is submitted in the revised version, and here, the differences are significant.

Reviewer \#3: General Impressions:

In this manuscript, the authors performed a feeding trial on Atlantic salmon in which fish were fed fish meal or soybean meal-based diets that were supplemented with varying amounts of Canadis utilis yeast. Changes in intestinal morphology and the plasma proteome of the fish were monitored at several points in the study in order to monitor both intestinal and systemic effects of the different diets.

Overall, the experimental design appears valid and the data collection and analysis of the histological data is appropriate. However, in the eyes of this reviewer, the analysis of the plasma proteomics data could be improved to allow for more meaningful interpretation of the data. The current methodology does not provide significant evidence that the observed changes in the plasma proteome are related to the differences in diet. However, after the authors address the following comments, the manuscript would likely be suitable for publication.

Major Comments:

The authors relied primarily on Spearman's correlation coefficients to identify proteins of interest from the plasma proteomics data. Therefore, the authors are essentially looking for cases where protein abundances do or do not correlate across the different diets. However, since there is a clear control in the experiment (fish meal-based diet), it seems that comparing all protein abundance to that control would be more informative. Then, emphasis would be placed on proteins that have 'abnormal' expression relative to the fishmeal fed fish. This would also allow for volcano plots to be generated and included in the manuscript, which would aid reader understanding.

Yes, we re-analyzed the data. According to your suggestions, we have generarted the volcano plots and heat maps, by comparing each diet treatment to the control (FM). The old heatmap figure is replaced with new heatmaps (Fig 6C) and new volcano plots were added (Fig 7A, 7B, 7C).

• Further description of how the quantitative values used in the proteomics analysis is needed. It appears that precursor abundance (from the MS1 scans) were used, but that is not explicitly stated. If that is the case, was peak intensity or peak area used? Also, was the 'match between runs' feature enabled in MaxQuant?

We performed the anlysis in Mascot and MaxQuant, however, we used the LFQ on MS2 level (Spectral count) and not on MS1 (Peak areas) as in MaxQuant to perform the analysis. The MS raw file were analyzed in both Mascot and Scaffold to get higher confidence in the protein identified.

• A table showing all of the proteins identified in the plasma analyses and their quantitative values should be provided in the supplement. Ideally, fold change values should also be included. It's possible that such a table was uploaded to PRIDE, but the PXD number provided does not bring up any results when searched. This is likely because the dataset has not been publicly released but the login info should be provided to reviewers.

Yes, an excel sheet containing all the proteins identified with their quantitative values and fold change values are submitted as a supplementary table (S3 Table).

• It is concerning that the fishmeal-based and soybean-based diets don't cluster in either the heatmap or the PCA plots. It seems likely that such large differences in the feed would causes systemic changes in the blood which would lead to high correlation between the D1 and D7 samples, but that was not observed. This suggests that either the analysis method was flawed, or that individual variation was too large in order to adequately detect differences from the feed.

It is important to mention that we did not observe severe enteritis on the SBM fed fish, which might have influenced the results on plasma proteome. On the other hand, as mentioned by Reviewer 3, we observed a very big variation between individual. This is a persistent concern in feeding trial with fish, since there is not an available method to measure individual feed intake as in mammals. Therefore we use each tank as unit and calculate feed intake per tank. Although we perform histology to verify the degree of enteritis of each fish used in the analysis, we are not sure how much of the antinutrient (SBM) each fish ingested. Our main aim goal was to identify proteins uniquely expressed in each group, but it seems at SBM enteritis is restricted to a local inflammation (distal intestine) instead of a systemic inflammation.

• Although this reviewer is not well versed in the VIP method used here, it seems that this technique is likely to put too much emphasis on proteins that are correlated purely by chance. Further justification of this technique should be included, or the analyses should be removed.

In the initial PCA plot (Fig 7D), there is significant overlap of dietary groups, which leads to difficulty in discerning which proteins are responsible for the changes seen between the dietary groups. To address this problem, we used a known approach (Eriksson L, Umetrics AB (2006) Multi- and Megavariate Data Analysis, Part 1, Basic Principles and Applications: Umetrics AB.) using Partial Least Squares -- Discriminant Analysis (PLS-DA) Variable Importance Projection (VIP) scores to highlight the significant changes between these groups. These VIP scores are normally used for variable selection as heat maps combined with group difference proteins to highlight the significant differences in dietary groups. We don't think, this VIP proteins are correlated purely by chance, as in the discussion, we have highlighted about the role of these proteins on immune system and how they are related with SBM enteritis.

• It would be helpful if the reviewers included a few representative images of the changes in morphology observed between the groups that are summarized in Fig. 2. This could be included as an additional supplemental figure.

We added Fig. 2S, where morphologic changes are presented due to the diets.

Minor Comments:

• L252: The fragment ion tolerance used here is much too large for orbitrap data. A tolerance of 0.02 Da would be more appropriate.

We appreciate the comment of Reviewer 3, the MS analysis was performed at Proteomic Core Facility of University of Oslo. But the recommendation will be taken into account in our future analysis.

• L253: Where was the salmon proteome database derived from? Was it a public repository such as uniprot? If so, when was it downloaded?

The reference salmon proteome was download from a public repository UniProt, as mention in the main text. The date of downloaded was December 2017.

• L316: No data is shown in this figure where SBM + C. utilis was fed first, followed by FM. This sentence says otherwise.

All the groups are included in the new figure.

• Fig. 4 caption -- L371: What is meant hear by 'data are expressed as mean � SD for each individual'? Isn't each point just representative of the mean for each fish? This should be clarified.

Data are expressed as the mean for all individuals � SD.

• L407-408: It doesn't make sense to say that proteins 'belong' to a specific domain. Please revise.

Yes, we revised the sentence and changed to "most of the proteins have signal protein domain".

• Fig. 7 caption -- L424: What do the colors in panel C represent? Also, why are proteins with VIP scores \< 2 included here?

The colors in the panel C represents the protein abundance at 4 dietary treatments. Red represents higher and dark green represents lower abundance. This sentence is added to the figure legend. We have replaced the figure with new one showing the proteins only with VIP \>2.

• L473: Remove 'DI.'

This line has been rewritten as part of the rearrangement of the discussion.

• L476: Change considering to considered.

This line has been rewritten as part of the rearrangement of the discussion.

###### 

Submitted filename: Reviewers comments_resubmission.docx
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Click here for additional data file.
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13 Sep 2019

PONE-D-19-15096R1

Candida utilis yeast as a functional protein source for Atlantic salmon (Salmo salar L.): Local intestinal tissue and plasma proteome responses

PLOS ONE

Dear Dr. Øverland,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

While all three reviewers consider the general response to comments satisfactory and that the manuscript is significantly improved, Reviewer 3 has underlined new concerns regarding the proteomic data analysis. Based on the possibility that the conclusion reached in the manuscript may be based on invalid interpretation of the results. The reviewer kindly suggests many viable options to overcome this conundrum, and I am therefore confident that the matter can be resolved.

Specific comments by both reviewers 2 and 3 should also be addressed prior to publication.

We would appreciate receiving your revised manuscript by Oct 28 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Annie Angers, Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: I have now been through this revised version of the manuscript. I am generally happy with all the authors responses to my original review. So I am happy to hereby recommend the manuscript for publication.

But I do have a few minor comments to help with some final improvements:

1\)

Regarding the Y-axes labels on figure 2, it may be more appropriate to label them \"Change\" rather than \"Scale\" that seems not very informative.

2\)

I suggest that the authors either delete or re-write the very kast sentence of the discussion:

\"Further research is needed to evaluate the impact of yeast strain and the fermentation

and/or down-stream processing conditions of the yeast on functional properties in relation to gastro

intestinal health and systemic responses.\"

As is, this is not very informative. Consider adding some more concrete suggestions as to how such \"Further research\" can be designed to better help move this entire research field and add more values to readers of the paper.

Reviewer \#3: The authors addressed a number of concerns raised by the reviewers and the manuscript has been significantly improved. Unfortunately, this reviewer still has significant concerns about the analysis of the proteomics data and the conclusions that are drawn from this data.

In the original manuscript, it was not made clear that the authors were utilizing spectral counting to obtain quantitative information from the proteomics data. This should have been stated in the manuscript, and needs to be added. The spectral counting method has been phased out in the field due to its low reproducibility and accuracy. When using a high resolution, accurate mass instrument such as the Q Exactive that was used here, MS1 intensity-based quantitation provides far superior quantitative values than does spectral counting. The reasons for this are well described in the literature, but are primarily the result of the somewhat stochastic nature of the data collection when data-dependent acquisition strategies are employed (as was done in this study). The fact that an MS2 mass tolerance was used for searching that was more than an order of magnitude higher than it should have been (0.8 Da rather than 0.02 Da) further reduces the quantitative accuracy of the spectral counting strategy used here.

For the reasons described above, the quantitative values presented should be treated with caution. The proteins shown to be differentially expressed in the volcano plots (Fig. 7) are likely valid, as this analysis incorporates both the calculated fold change, as well as a p-value, which incorporates other variables such as inter-sample variability. Unfortunately, many of the proteins that the authors focus on in the discussion (such as HMP, LYME, and HIIN) were not shown to be differentially expressed by this analysis, they simply didn\'t correlate well to the control. This alone is not adequate evidence of a change in protein abundance.

With these concerns in mind, this reviewer suggests the authors choose one of 3 options:

1\. Reanalyze the data using MS1 intensity-based quantitation (as can be completed in MaxQuant or other software packages such as Scaffold Q+, Proteome Discoverer, etc.).

2\. Focus the discussion only on proteins that showed differential abundance in the volcano plot analyses (Fig. 7)

3\. Remove the proteomics data entirely and focusing on the gene expression, morphological, and other data presented in the manuscript.

Any of the above approaches would be valid and would make the publication suitable for publication in the opinion of this reviewer.

Specific Comments:

L262: The date the database was downloaded should also be included.

L403: Don\'t say \'expressed\' here. The proteins were likely expressed in the samples, they just couldn\'t be detected by the mass spectrometer.

Figure 6: The Spearman\'s correlations done here do not provide sufficient evidence to say a protein is changing abundance. Panel C should be removed from the manuscript as well as all discussion of the results presented in this panel.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0218360.r004

Author response to Decision Letter 1

28 Oct 2019

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: I have now been through this revised version of the manuscript. I am generally happy with all the authors responses to my original review. So I am happy to hereby recommend the manuscript for publication.

But I do have a few minor comments to help with some final improvements:

1\)

Regarding the Y-axes labels on figure 2, it may be more appropriate to label them \"Change\" rather than \"Scale\" that seems not very informative.

The label on the Y-axis has been changed from \"scale\" to \"change\" according to the reviewer's request.

2\)

I suggest that the authors either delete or re-write the very kast sentence of the discussion:

\"Further research is needed to evaluate the impact of yeast strain and the fermentation and/or down-stream processing conditions of the yeast on functional properties in relation to gastro intestinal health and systemic responses.\"

As is, this is not very informative. Consider adding some more concrete suggestions as to how such \"Further research\" can be designed to better help move this entire research field and add more values to readers of the paper.

The last sentence has been deleted as the discussion has been changed.

Reviewer \#3: The authors addressed a number of concerns raised by the reviewers and the manuscript has been significantly improved. Unfortunately, this reviewer still has significant concerns about the analysis of the proteomics data and the conclusions that are drawn from this data.

In the original manuscript, it was not made clear that the authors were utilizing spectral counting to obtain quantitative information from the proteomics data. This should have been stated in the manuscript, and needs to be added. The spectral counting method has been phased out in the field due to its low reproducibility and accuracy. When using a high resolution, accurate mass instrument such as the Q Exactive that was used here, MS1 intensity-based quantitation provides far superior quantitative values than does spectral counting. The reasons for this are well described in the literature, but are primarily the result of the somewhat stochastic nature of the data collection when data-dependent acquisition strategies are employed (as was done in this study). The fact that an MS2 mass tolerance was used for searching that was more than an order of magnitude higher than it should have been (0.8 Da rather than 0.02 Da) further reduces the quantitative accuracy of the spectral counting strategy used here.

For the reasons described above, the quantitative values presented should be treated with caution. The proteins shown to be differentially expressed in the volcano plots (Fig. 7) are likely valid, as this analysis incorporates both the calculated fold change, as well as a p-value, which incorporates other variables such as inter-sample variability. Unfortunately, many of the proteins that the authors focus on in the discussion (such as HMP, LYME, and HIIN) were not shown to be differentially expressed by this analysis, they simply didn\'t correlate well to the control. This alone is not adequate evidence of a change in protein abundance.

With these concerns in mind, this reviewer suggests the authors choose one of 3 options:

1\. Reanalyze the data using MS1 intensity-based quantitation (as can be completed in MaxQuant or other software packages such as Scaffold Q+, Proteome Discoverer, etc.).

2\. Focus the discussion only on proteins that showed differential abundance in the volcano plot analyses (Fig. 7)

3\. Remove the proteomics data entirely and focusing on the gene expression, morphological, and other data presented in the manuscript.

Any of the above approaches would be valid and would make the publication suitable for publication in the opinion of this reviewer.

We are grateful for the specificity and professional comments of reviewer 3. We decided to take option number 1, which means at we reanalyzed the entire dataset using MaxQuant and Perseus. The LFQ intensities were exported to an excel sheet. The log-transformed LFQ values were analyzed using the pipeline described in material and methods. We created volcano plots, comparing the protein pattern of each dietary treatment with the control diet. This comparison resulted in 9, 12 and 10 significantly expressed protein when the FM was compared with SBM, SBM200CU and FM200CU, respectively. Although option 1 was more complicated, we are very grateful for the comments, which helped us to increase the reliability of our results.

Specific Comments:

L262: The date the database was downloaded should also be included.

We used the latest salmon proteome available and the date is included in the manuscript

L403: Don\'t say \'expressed\' here. The proteins were likely expressed in the samples, they just couldn\'t be detected by the mass spectrometer.

The sentence was changed as marked in the manuscript.

Figure 6: The Spearman\'s correlations done here do not provide sufficient evidence to say a protein is changing abundance. Panel C should be removed from the manuscript as well as all discussion of the results presented in this panel.

In accordance with the reviewer's advice, Panel C in Figure 6 has been removed from the manuscript and the discussion revised accordingly.
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Submitted filename: Response to Reviewers.docx
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PONE-D-19-15096R2

Candida utilis yeast as a functional protein source for Atlantic salmon (Salmo salar L.): Local intestinal tissue and plasma proteome responses

PLOS ONE

Dear Dr. Øverland,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript is much improved and almost ready for publication. However, the final concerns raised by Reviewer 3 still need to be addressed, and minor adjustments to the text are also needed.

We would appreciate receiving your revised manuscript by Dec 26 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Annie Angers, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

\- Please address the possible data discrepancies between table S3 and table 2 referred to by Reviewer 3;

\- Make sure that proteins that were not found in a replicate are not given a value of zero but treated as missing in your analysis (or clearly state that you did not use 0 in your analysis)

\- Make the minor adjustments to text suggested by Reviewer 3.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#3: General Impressions:

The authors have clearly addressed the concerns raised in the previous review, and the reanalysis of the proteomics data has dramatically improved the quality of the manuscript. I greatly appreciate the authors hard work and dedication to providing the highest quality data possible. I have noticed one discrepancy in the data analysis that should be addressed in the final version of the manuscript (described below), but I feel that the manuscript is otherwise ready for publication. I've also included a few very minor comments that I feel will improve the readability of the publication.

Major Comments:

The authors state that only protein that were identified in at least two of the four replicates were used for quantitative analysis. However, when looking at Table S3 and comparing that to the results presented in Table 2, there seems to be some discrepancies. For example, C0HAL2 (elongation factor 1-alpha) is reported as having a very significant fold-change between the FM (D1) and SBM (D2) in Table 2, yet no quantitative values for this protein are reported in the D2 group in Table S3. Why is this? Please ensure that your filtering is working as intended.

Additionally, proteins that were not identified in a replicate should not be assigned a quantitative value of 0. Instead, these values should be treated as missing (null), or missing value imputation should be used to provide baseline quantitative values. It's difficult to determine how such values were treated in the analysis, and that should be stated outright.

As an aside for future experiments, use of the 'match between runs' feature in MaxQuant should dramatically decrease the number of missing values present in the dataset.

Minor Comments:

Line 241: It seems as if part of this sentence was accidentally removed as there is no mention of the addition of trypsin.

Line 243: Another sentence or two very briefly describing the column and MS parameters that were used would be useful here.

Line 261: Was a fragment mass tolerance of 0.8 used in the reprocessed data as well or was this a carryover from the previous version of the manuscript? As mentioned previously, a much tighter tolerance (\~0.02 Da) would be more appropriate.

Lines 276-277: Saying that the average weights increased does not mean that every fish gained weight. Consider rephrasing.

Table 2: It would be nice if you included the p-value for each protein here as well.

Figure 6: As a note, the 'presence' of a protein in one sample and not in another is much more likely a result of the stochastic nature of the MS data collection rather than a protein actually being present in the sample or not. Therefore, comparisons such as the one shown here are often not very informative.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#3: General Impressions:

The authors have clearly addressed the concerns raised in the previous review, and the reanalysis of the proteomics data has dramatically improved the quality of the manuscript. I greatly appreciate the authors hard work and dedication to providing the highest quality data possible. I have noticed one discrepancy in the data analysis that should be addressed in the final version of the manuscript (described below), but I feel that the manuscript is otherwise ready for publication. I've also included a few very minor comments that I feel will improve the readability of the publication.

Major Comments:

The authors state that only protein that were identified in at least two of the four replicates were used for quantitative analysis. However, when looking at Table S3 and comparing that to the results presented in Table 2, there seems to be some discrepancies. For example, C0HAL2 (elongation factor 1-alpha) is reported as having a very significant fold-change between the FM (D1) and SBM (D2) in Table 2, yet no quantitative values for this protein are reported in the D2 group in Table S3. Why is this? Please ensure that your filtering is working as intended.

\--\> We follow the criteria "at least two peptides in at least half of the replicates" per group. It means to asseverate that a protein is present in one or all the groups, should be at least in two samples. As an example, protein C0HAL2 is detected in all replicated of diet 1, in one of the replicates on diet 6 and in three out of the four replicates on diet 7. It was not detected on diet 2, therefore the significant difference between diet 1 and diet 2. From the total 158 proteins, 126 proteins were present in all dietary treatment, however the other 32 proteins were present in either one, two or three of the treatment, not in all, as stated in the manuscript.

Additionally, proteins that were not identified in a replicate should not be assigned a quantitative value of 0. Instead, these values should be treated as missing (null), or missing value imputation should be used to provide baseline quantitative values. It's difficult to determine how such values were treated in the analysis, and that should be stated outright.

\--\> The function missing value imputation was used for the quantitative analysis. The imputed value is shown in Table S3 and it is mentioned in the manuscript as follow:

"Protein raw data were transferred to log normalization; missing value imputation was used to replace the not identified proteins on the quantitative analysis and then performed on autoscaled data (mean-centered and divided by the standard deviation of each variable) \[29\]."

As an aside for future experiments, use of the 'match between runs' feature in MaxQuant should dramatically decrease the number of missing values present in the dataset.

\--\> We are very grateful for the suggestions, we have been learning a lot in this process so we are confident that in future experiments we will take into practice the knowledge acquired.

Minor Comments:

Line 241: It seems as if part of this sentence was accidentally removed as there is no mention of the addition of trypsin.

\--\> Yes, it was an editing mistake. The sentence has been rewritten as follow:

"Subsequently, the proteins were digested with 10 μg trypsin (Promega, sequencing grade) overnight at 37°C. The digestion was stopped by adding 5 μL 50% formic acid and the generated peptides were purified using a ZipTip C18 (Millipore, Billerica, MA, USA) according to the manufacturer's instructions, and dried using a Speed Vac concentrator (Concentrator Plus, Eppendorf, Hamburg, Germany)"

Line 243: Another sentence or two very briefly describing the column and MS parameters that were used would be useful here.

\--\> The information required was added into the text

"The tryptic peptides were dissolved in 10 µL 0.1% formic acid/2% acetonitrile and 5 µL analyzed using an Ultimate 3000 RSLCnano-UHPLC system connected to a Q Exactive mass spectrometer (Thermo Fisher Scientiﬁc, Bremen, Germany) equipped with a nanoelectrospray ion source. For liquid chromatography separation, an Acclaim PepMap 100 column (C18, 2 µm beads, 100 Å, 75 μm inner diameter, 50 cm length) (Dionex, Sunnyvale CA, USA) was used. The mass spectrometer was operated in the data-dependent mode to automatically switch between MS and MS/MS acquisition. Survey full scan MS spectra (from m/z 400 to 2,000) were acquired with the resolution R = 70,000 at m/z 200, after accumulation to a target of 1e5. The maximum allowed ion accumulation times were 60 ms"

Line 261: Was a fragment mass tolerance of 0.8 used in the reprocessed data as well or was this a carryover from the previous version of the manuscript? As mentioned previously, a much tighter tolerance (\~0.02 Da) would be more appropriate.

\--\> This corresponded to the previous analysis, the new analysis was performed using:

"The fragment mass tolerance for the MS1 was 6 ppm and the fragment mass tolerance for the MS2 was 20 ppm".

This information was added into the text

Lines 276-277: Saying that the average weights increased does not mean that every fish gained weight. Consider rephrasing.

\--\> The sentence was rephrased as follow:

"The average initial weight was 526 g and the average final 277 weight was 667 g on day 37, considering that the weight was measured as bulk, this indicates that in general fish gained weight during the experimental period"

Table 2: It would be nice if you included the p-value for each protein here as well.

\--\> We have included the p-value in Table 2 as required by Reviewer 3.

Figure 6: As a note, the 'presence' of a protein in one sample and not in another is much more likely a result of the stochastic nature of the MS data collection rather than a protein actually being present in the sample or not. Therefore, comparisons such as the one shown here are often not very informative.

\--\> We are grateful for the comments and it will be considered in our future experiments.
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Dear Dr. Øverland,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Annie Angers, Ph.D.
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Additional Editor Comments (optional):

Thank you for the extensive revisions to the manuscript. I am sorry that the processed took so long, but I feel that the improved version was worth the efforts.
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